GENEMEDICS APP
GENEMEDICS NUTRITION
Pregnenolone is a steroid hormone produced primarily in the adrenal glands. Smaller amounts of pregnenolone are also produced in other organs such as the brain, skin, gonads, liver, and eyes. In the body, all hormones work in harmony to create a healthy balance. If you picture steroid hormones as a cascade, where one hormone has an impact on one another, pregnenolone would be at the top of the cascade.
Pregnenolone is manufactured directly from cholesterol – which is one reason why experts believe that below the normal levels of cholesterol can cause hormonal imbalance. In turn, several other hormones including testosterone, DHEA, estrogen, and cortisol are synthesized from pregnenolone that’s why it is called as the “mother of all steroid hormones”. Just as it’s used to synthesize other steroid hormones, adequate amounts of pregnenolone are used to create neurohormones in the brain, which act to maintain healthy nerve cell function and regulate mood.
Pregnenolone has several important functions in the body aside from acting as the main precursor for most steroid hormones. It seems to have a balancing effect to many other hormones by increasing or decreasing their levels when necessary. In addition, pregnenolone also regulates the transmission of messages between each nerve cell (neuron) to strongly influence many other processes in the brain and other body systems.
As we age, the levels of pregnenolone fall dramatically to as much as 60 percent. Researchers have linked this hormonal imbalance to a wide array of debilitating medical conditions that can affect overall quality of life. Unpleasant symptoms related to low pregnenolone include:
Several Bioidentical hormone replacement programs tend to use pregnenolone because it is touted as the “mother of all steroid hormones”, thus, it can boost overall health by bringing the levels of other vital hormones up as needed. In fact, pregnenolone is effectively used in conjunction with testosterone and estrogen to help relieve various symptoms of menopause and andropause (male menopause). With pregnenolone supplementation, the goal is to support overall healthy levels of this hormone in order to stimulate the body to produce internal pregnenolone in areas that need a boost of another steroid hormone. This powerful hormone is available in the form of injections, tablets, and topical creams. Strong scientific evidence suggests that different modes of prenenolone administration are highly safe and effective in treating various medical conditions and improving overall health:
Pregnenolone is a nootropic agent or “cognitive enhancer”. This means that it has the ability to improve various aspects of cognitive function including memory, learning, and thinking skills. Studies show that pregnenolone boosts cognitive function through several important mechanisms:
In both men and women, pregnenolone deficiency can dramatically affect sleeping pattern and quality. As a pro-hormone responsible for the production of several vital sex hormones, pregnenolone in its healthy levels can stimulate deep sleep. Research into sleep is showing a strong connection between pregnenolone and its ability to promote normal sleep pattern:
Schizophrenia is a long-term mental health condition that causes a wide array of psychological symptoms such as hallucinations, delusions, muddled thoughts, and changes in behavior. Currently, treatment for schizophrenia includes antipsychotic medicines and cognitive behavioral therapy (talking therapy). There is increasing evidence that pregnenolone administration can be considered as a therapeutic option for this debilitating mental condition:
Decreased levels of pregnenolone are strongly linked with depressed mood. [83-84] Because depression can be very challenging to treat, with current medications requiring months before its therapeutic effects are achieved, research into pregnenolone on mood can be a game-changer. Interestingly, clinical studies assessing the beneficial effects of pregnenolone on mood, depression, anxiety, and other mental disorders show positive results:
With advancing age, the immune system weakens making us susceptible to various infections. Interestingly, pregnenolone does have immune-modulating properties that can help boost the immune response, thereby warding off a wide array of diseases. Strong scientific evidence supports the beneficial effects of pregnenolone on the immune system:
Chronic alcohol intake significantly increases the risk of liver disease and other fatal medical conditions. Studies show that pregnenolone administration may offer long-term solution to chronic alcoholism:
In addition to its already potent neuroprotective properties, pregnenolone might also be able to combat certain types of cancer. There is strong scientific evidence that supports the cancer-fighting properties of pregnenolone:
Marijuana, also known as cannabis, is the most commonly used illegal drug in the world. While some states or countries permit its use, chronic marijuana administration can lead to serious side effects such as panic attack, intense anxious or fearful feelings and thoughts, and acute psychosis. With its neuroprotective properties, studies show that pregnenolone may help protect against the negative effects cannabis intoxication:
The logic behind the cholesterol-lowering effect of pregnenolone is simple – it is manufactured directly from cholesterol. To put it simply, when pregnenolone levels increase, cholesterol levels decrease. Studies on pregnenolone support its cholesterol-lowering effects:
Sexual desire and function declines with advancing age. This is because the levels of many other hormones that regulate sex drive (testosterone and estrogen) also decline gradually. As the “mother of all hormones”, studies show that pregnenolone can help restore youthful levels of other hormones, thereby ramping up sexual power:
Mayo W, Le Moal M, Abrous DN. Pregnenolone sulfate and aging of cognitive functions: behavioral, neurochemical, and morphological investigations. Hormones and behavior. 2001; 40(2):215-7.
Pregnenolone sulfate and aging of cognitive functions
The study “Pregnenolone Sulfate and Aging of Cognitive Functions: Behavioral, Neurochemical, and Morphological Investigations” investigates the role of neurosteroids, specifically pregnenolone sulfate (PREG-S), in cognitive functions. It was found that PREG-S levels correlated with cognitive performance in aged animals. Memory deficits in these animals were reversible with PREG-S infusions. The study also discovered that PREG-S enhances acetylcholine release in the brain, which is vital for memory and affected in aging and Alzheimer’s disease. Additionally, PREG-S might impact hippocampal neurogenesis, suggesting its potential role in improving cognitive functions in older subjects.
For further details visit https://pubmed.ncbi.nlm.nih.gov/11534985/
Ducharme N, Banks WA, Morley JE, Robinson SM, Niehoff ML, Mattern C. Brain distribution and behavioral effects of progesterone and pregnenolone after intranasal or intravenous administration. European journal of pharmacology. 2010;641(2-3):128-134. doi:10.1016/j.ejphar.2010.05.033.
Brain distribution and behavioral effects of progesterone and pregnenolone after intranasal or intravenous administration
The study “Brain Distribution and Behavioral Effects of Progesterone and Pregnenolone after Intranasal or Intravenous Administration” investigated how these neurosteroids are distributed in the brain and their behavioral effects when administered intranasally or intravenously. It found differences in brain distribution and serum levels based on the method of administration. The study also explored the impact of intranasal pregnenolone on memory and intranasal progesterone on anxiety, revealing specific effects on these behavioral aspects.
For further details visit https://pubmed.ncbi.nlm.nih.gov/20570588/
Marx CE, Keefe RS, Buchanan RW, et al. Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2009;34(8):1885-1903. doi:10.1038/npp.2009.26.
Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia
The study “Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia” conducted by Marx CE, Keefe RS, Buchanan RW, and others, was a randomized controlled trial investigating the effects of pregnenolone, a neurosteroid, on schizophrenia. The trial aimed to assess the impact of pregnenolone on cognitive and negative symptoms associated with schizophrenia.
In the study, 120 participants with schizophrenia were randomized to receive either pregnenolone or a placebo for 8 weeks. The primary endpoints of the study were changes in the MATRICS Consensus Cognitive Battery (MCCB) composite scores, which assess cognitive symptoms; UCSD Performance-based Skills Assessment-Brief (UPSA-B) composite scores, evaluating functional capacity; and the Scale for Assessment of Negative Symptoms (SANS) total scores.
For further details visit https://pubmed.ncbi.nlm.nih.gov/19339966/
Vallée M, Vitiello S, Bellocchio L, et al. Pregnenolone Can Protect the Brain from Cannabis Intoxication. Science (New York, NY). 2014;343(6166):94-98. doi:10.1126/science.1243985.
Pregnenolone Can Protect the Brain from Cannabis Intoxication
The study by Vallée et al. titled “Pregnenolone Can Protect the Brain from Cannabis Intoxication,” published in Science in 2014, explored the neuroprotective effects of pregnenolone, a neurosteroid, against the intoxicating effects of cannabis. The researchers found that THC, the primary psychoactive component of cannabis, significantly increases pregnenolone levels in various brain regions, including the nucleus accumbens (NAc), when administered to rats and mice. This increase in pregnenolone levels was observed to be substantially higher compared to other drugs of abuse like cocaine, morphine, nicotine, and ethanol.
Interestingly, the study also discovered that while THC led to a dramatic increase in pregnenolone levels, the levels of pregnenolone metabolites were only marginally increased or remained unchanged. These findings suggest that pregnenolone acts as a neuroactive steroid and not just as a precursor to other steroids. The research highlights pregnenolone’s potential role in mitigating the effects of cannabis intoxication and opens up possibilities for new therapeutic approaches for cannabis addiction.
For further details visit https://www.nature.com/articles/nrn3681
Flood JF, Morley JE, Roberts E. Memory-enhancing effects in male mice of pregnenolone and steroids metabolically derived from it. Proceedings of the National Academy of Sciences of the United States of America. 1992;89(5):1567-1571.
Memory-enhancing effects in male mice of pregnenolone and steroids metabolically derived from it
The study “Memory-enhancing effects in male mice of pregnenolone and steroids metabolically derived from it,” conducted by Flood, Morley, and Roberts, examined the impact of pregnenolone and related steroids on memory retention in mice. The research demonstrated that administering certain steroids, including pregnenolone (P), pregnenolone sulfate (PS), and others, immediately after training improved retention for footshock active avoidance training in male mice. P and PS were found to be particularly potent, with PS showing significant effects at very low doses. This study suggests a potential role for these steroids in enhancing memory and highlights the complexity of their action mechanisms, potentially involving the modulation of gene transcription related to memory processes. The study also indicates possible clinical applications for pregnenolone due to its memory-enhancing capabilities.
For further details visit https://pubmed.ncbi.nlm.nih.gov/1531874/
Vallée M, Mayo W, Le Moal M. Role of pregnenolone, dehydroepiandrosterone and their sulfate esters on learning and memory in cognitive aging. Brain research. Brain research reviews. 2001; 37(1-3):301-12.
Role of pregnenolone, dehydroepiandrosterone and their sulfate esters on learning and memory in cognitive aging
The study “Role of pregnenolone, dehydroepiandrosterone, and their sulfate esters on learning and memory in cognitive aging” by Vallée, Mayo, and Le Moal, focuses on the potential role of neurosteroids in cognitive aging. The review compiles data from animal and human studies, suggesting that neurosteroids like pregnenolone (PREG) and dehydroepiandrosterone (DHEA), along with their sulfate derivatives, may enhance memory in aged rodents. While some human studies found improvements in cognitive functions following DHEA administration, especially in individuals with low DHEAS levels, other studies yielded contradictory results, showing no significant cognitive effects. This indicates a complex relationship between neurosteroids and cognitive aging, necessitating further research for a better understanding, particularly in the context of normal and pathological aging like Alzheimer’s disease.
For further details visit https://pubmed.ncbi.nlm.nih.gov/11744095/
Wong P, Chang CCR, Marx CE, Caron MG, Wetsel WC, Zhang X. Pregnenolone Rescues Schizophrenia-Like Behavior in Dopamine Transporter Knockout Mice. Hashimoto K, ed. PLoS ONE. 2012;7(12):e51455. doi:10.1371/journal.pone.0051455.
Pregnenolone Rescues Schizophrenia-Like Behavior in Dopamine Transporter Knockout Mice
The study “Pregnenolone Rescues Schizophrenia-Like Behavior in Dopamine Transporter Knockout Mice” explored the effects of pregnenolone in mice lacking dopamine transporters, a model for certain symptoms of schizophrenia. The research demonstrated that pregnenolone treatment in these mice reduced hyperactivity and stereotypic behaviors, and improved prepulse inhibition and memory deficits. These findings suggest that pregnenolone could be a potential therapeutic agent for treating certain symptoms of schizophrenia.
For further details visit https://pubmed.ncbi.nlm.nih.gov/23240026/
Ritsner MS, Bawakny H, Kreinin A. Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial. Psychiatry and clinical neurosciences. 2014; 68(6):432-40.
Pregnenolone treatment reduces severity of negative symptoms in recent‐onset schizophrenia: An 8‐week, double‐blind, randomized add‐on two‐center trial
The study “Pregnenolone treatment reduces the severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial” by Ritsner, Bawakny, and Kreinin examined the effects of pregnenolone as an adjunct treatment in patients with recent-onset schizophrenia. The trial aimed to assess the impact of pregnenolone on the severity of negative symptoms associated with schizophrenia. Over 8 weeks, the study found that pregnenolone treatment resulted in a reduction in the severity of these negative symptoms, suggesting its potential as a therapeutic agent in managing schizophrenia.
For an in-depth analysis of this study visit https://onlinelibrary.wiley.com/doi/abs/10.1111/pcn.12150
Smith CC, Gibbs TT, Farb DH. Pregnenolone sulfate as a modulator of synaptic plasticity. Psychopharmacology. 2014;231(17):3537-3556. doi:10.1007/s00213-014-3643-x.
Pregnenolone sulfate as a modulator of synaptic plasticity
The study “Pregnenolone Sulfate as a Modulator of Synaptic Plasticity,” conducted by Smith, Gibbs, and Farb, focuses on the role of pregnenolone sulfate (PS), a neurosteroid, in synaptic plasticity. The research highlights the potential of PS to modulate various aspects of synaptic function, suggesting its influence on cognitive processes and mental health. The study provides insight into the neuropharmacological mechanisms of PS and its implications for conditions like schizophrenia and age-related cognitive decline.
For an in-depth analysis of this study visit https://link.springer.com/article/10.1007/s00213-014-3643-x
Mellon SH. Neurosteroid regulation of CNS development. Pharmacology & therapeutics. 2007;116(1):107-124. doi:10.1016/j.pharmthera.2007.04.011.
Neurosteroid regulation of CNS development
The study “Neurosteroid Regulation of CNS Development” by Mellon SH explores the impact of neurosteroids, particularly during the development of the central nervous system (CNS). The research underscores the vital role that neurosteroids play in the growth and maturation of the CNS. It highlights how these compounds influence various developmental processes, including neural proliferation, survival, differentiation, and myelination. This study provides crucial insights into the neurochemical mechanisms that underpin CNS development and the potential influence of neurosteroids on neurodevelopmental disorders.
For an in-depth analysis of this study visit https://www.sciencedirect.com/science/article/pii/S016372580700109X
Yang R, Zhou R, Chen L, et al. Pregnenolone sulfate enhances survival of adult-generated hippocampal granule cells via sustained presynaptic potentiation. Neuropharmacology. ; 60(2-3):529-41.
Pregnenolone sulfate enhances survival of adult-generated hippocampal granule cells via sustained presynaptic potentiation
The study “Pregnenolone Sulfate Enhances Survival of Adult-Generated Hippocampal Granule Cells via Sustained Presynaptic Potentiation” by Yang et al. investigates the effects of pregnenolone sulfate (PS) on the survival of newly generated granule cells in the hippocampus. The research suggests that PS promotes the survival of these cells through mechanisms involving sustained presynaptic potentiation. This finding highlights the potential role of neurosteroids like PS in neurogenesis and synaptic function, contributing to our understanding of brain plasticity and cognitive health.
For more detailed information https://www.sciencedirect.com/science/article/pii/S0028390810003163
Weng JH, Liang MR, Chen CH, et al. Pregnenolone activates CLIP-170 to promote microtubule growth and cell migration. Nature chemical biology. 2013; 9(10):636-42.
Pregnenolone activates CLIP-170 to promote microtubule growth and cell migration
The study “Pregnenolone Activates CLIP-170 to Promote Microtubule Growth and Cell Migration” by Weng et al. explores the role of pregnenolone, a neurosteroid, in cellular processes. The research demonstrates that pregnenolone activates the protein CLIP-170, a microtubule plus-end tracking protein, which in turn promotes the growth of microtubules. This process is crucial for various cellular functions, including cell migration. This discovery provides significant insights into the molecular mechanisms of cell motility and the potential roles of neurosteroids in cellular dynamics.
For more detailed information https://www.nature.com/articles/nchembio.1321
Veiga S, Garcia-Segura LM, Azcoitia I. Neuroprotection by the steroids pregnenolone and dehydroepiandrosterone is mediated by the enzyme aromatase. Journal of neurobiology. 2003; 56(4):398-406.
Neuroprotection by the steroids pregnenolone and dehydroepiandrosterone is mediated by the enzyme aromatase
The study “Neuroprotection by the steroids pregnenolone and dehydroepiandrosterone is mediated by the enzyme aromatase” by Veiga, Garcia-Segura, and Azcoitia investigates the neuroprotective role of pregnenolone and dehydroepiandrosterone (DHEA). It reveals that their neuroprotective effects are mediated through the enzyme aromatase, which converts these steroids into estrogen. This suggests that the conversion to estrogen is crucial for the neuroprotective properties of pregnenolone and DHEA. The study contributes to our understanding of the mechanisms behind steroid-mediated neuroprotection.
For more detailed information https://onlinelibrary.wiley.com/doi/abs/10.1002/neu.10249
Shirakawa H, Katsuki H, Kume T, Kaneko S, Akaike A. Pregnenolone sulphate attenuates AMPA cytotoxicity on rat cortical neurons. The European journal of neuroscience. 2005; 21(9):2329-35.
Pregnenolone sulphate attenuates AMPA cytotoxicity on rat cortical neurons
The study “Pregnenolone Sulphate Attenuates AMPA Cytotoxicity on Rat Cortical Neurons” by Shirakawa et al. investigates the protective effects of pregnenolone sulphate against cytotoxicity induced by AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) in rat cortical neurons. The findings demonstrate that pregnenolone sulphate can effectively reduce the toxic effects of AMPA on these neurons, suggesting a potential neuroprotective role for this neurosteroid in conditions characterized by excitotoxicity.
For more detailed information https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1460-9568.2005.04079.x
Morfin R, Courchay G. Pregnenolone and dehydroepiandrosterone as precursors of native 7-hydroxylated metabolites which increase the immune response in mice. The Journal of steroid biochemistry and molecular biology. 1994; 50(1-2):91-100.
Pregnenolone and dehydroepiandrosterone as precursors of native 7-hydroxylated metabolites which increase the immune response in mice
The study “Pregnenolone and Dehydroepiandrosterone as Precursors of Native 7-Hydroxylated Metabolites Which Increase the Immune Response in Mice” by Morfin and Courchay examines the impact of pregnenolone and dehydroepiandrosterone (DHEA) on the immune response in mice. It specifically focuses on their role as precursors for 7-hydroxylated metabolites, which are observed to enhance the immune response. This research adds to the understanding of the physiological roles of these steroids in immune function.
For more detailed information: https://www.sciencedirect.com/science/article/pii/0960076094901767
Chen CC, Parker CR. Adrenal androgens and the immune system. Seminars in reproductive medicine. 2004; 22(4):369-77.
Adrenal androgens and the immune system
The study “Adrenal Androgens and the Immune System” by Chen and Parker discusses the relationship between adrenal androgens, like DHEA and androstenedione, and the immune system. It explores how these hormones, produced by the adrenal glands, influence immune responses. The article provides insight into the complex interactions between endocrine and immune systems, highlighting the significant role of adrenal androgens in immunological activities.
For more detailed information: https://www.thieme-connect.com/products/ejournals/html/10.1055/s-2004-861553
Khorram O, Vu L, Yen SS. Activation of immune function by dehydroepiandrosterone (DHEA) in age-advanced men. The journals of gerontology. Series A, Biological sciences and medical sciences. 1997; 52(1):M1-7.
Activation of immune function by dehydroepiandrosterone (DHEA) in age-advanced men
The study “Activation of Immune Function by Dehydroepiandrosterone (DHEA) in Age-Advanced Men” by Khorram, Vu, and Yen SS investigates the effects of DHEA, a hormone produced by the adrenal glands, on immune function in older men. It specifically examines how DHEA supplementation might influence immune response, considering the decline in DHEA levels with age and its potential implications for age-related changes in immune function.
For more detailed information: https://academic.oup.com/biomedgerontology/article-abstract/52A/1/M1/550201
Dávola ME, Mazaira GI, Galigniana MD, Alché LE, Ramírez JA, Barquero AA. Synthetic pregnenolone derivatives as antiviral agents against acyclovir-resistant isolates of Herpes Simplex Virus Type 1. Antiviral research. 2015; 122:55-63.
Synthetic pregnenolone derivatives as antiviral agents against acyclovir-resistant isolates of Herpes Simplex Virus Type 1
The study “Synthetic Pregnenolone Derivatives as Antiviral Agents Against Acyclovir-Resistant Isolates of Herpes Simplex Virus Type 1” by Dávola et al. explores the antiviral potential of synthetic pregnenolone derivatives against strains of Herpes Simplex Virus Type 1 (HSV-1) resistant to acyclovir. This research investigates alternative treatments for HSV-1, especially in cases where conventional antiviral drugs are less effective
For more detailed information: https://www.sciencedirect.com/science/article/pii/S0166354215001886
Mahata B, Zhang X, Kolodziejczyk AA, et al. Single-Cell RNA Sequencing Reveals T Helper Cells Synthesizing Steroids De Novo to Contribute to Immune Homeostasis. Cell Reports. 2014;7(4):1130-1142. doi:10.1016/j.celrep.2014.04.011.
Single-Cell RNA Sequencing Reveals T Helper Cells Synthesizing Steroids De Novo to Contribute to Immune Homeostasis
The study “Single-Cell RNA Sequencing Reveals T Helper Cells Synthesizing Steroids De Novo to Contribute to Immune Homeostasis” by Mahata et al. explores the capacity of T helper cells to synthesize steroids de novo, contributing to immune homeostasis. This groundbreaking discovery, revealed through single-cell RNA sequencing, demonstrates a previously unrecognized function of T helper cells in the immune system. The findings suggest that these cells play a more complex role in maintaining immune balance than previously understood.
For more detailed information: https://www.cell.com/cell-reports/pdf/S2211-1247(14)00298-8.pdf
Petit GH, Tobin C, Krishnan K, et al. Pregnenolone sulfate and its enantiomer: differential modulation of memory in a spatial discrimination task using forebrain NMDA receptor deficient mice. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2011;21(2):211-215. doi:10.1016/j.euroneuro.2010.09.010.
Pregnenolone sulfate and its enantiomer
The study “Pregnenolone Sulfate and Its Enantiomer: Differential Modulation of Memory in a Spatial Discrimination Task Using Forebrain NMDA Receptor Deficient Mice” by Petit et al. examines the effects of pregnenolone sulfate and its enantiomer on memory modulation. The research specifically focuses on their impact in a spatial discrimination task in mice with deficient forebrain NMDA receptors. The findings contribute to the understanding of neurosteroids’ role in cognitive functions, particularly in the context of NMDA receptor function.
For more detailed information: https://www.sciencedirect.com/science/article/pii/S0924977X10002142
Bu J, Zu H. Effects of pregnenolone intervention on the cholinergic system and synaptic protein 1 in aged rats. The International journal of neuroscience. 2014; 124(2):117-24.
Effects of pregnenolone intervention on the cholinergic system and synaptic protein 1 in aged rats
The study “Effects of Pregnenolone Intervention on the Cholinergic System and Synaptic Protein 1 in Aged Rats” by Bu and Zu investigates the impact of pregnenolone on the cholinergic system and synaptic protein 1 in elderly rats. It aims to understand how pregnenolone supplementation could affect these aspects of the nervous system, which are crucial for cognitive functions and are often altered during aging. This research contributes to our knowledge of potential interventions for age-related cognitive decline.
For more detailed information: https://www.tandfonline.com/doi/abs/10.3109/00207454.2013.824437
Marx CE, Keefe RS, Buchanan RW, et al. Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2009;34(8):1885-1903. doi:10.1038/npp.2009.26.
Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia
The study “Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia” by Marx et al. explored the effects of pregnenolone supplementation on cognitive and negative symptoms in individuals with schizophrenia. The trial aimed to evaluate whether pregnenolone could improve these symptoms over 8 weeks. This research provides insights into potential new treatments for cognitive and negative symptoms in schizophrenia.
For more detailed information: https://www.nature.com/articles/npp200926
Mellon SH. Neurosteroid regulation of CNS development. Pharmacology & therapeutics. 2007;116(1):107-124. doi:10.1016/j.pharmthera.2007.04.011.
Neurosteroid regulation of CNS development. Pharmacology & therapeutics
The study “Neurosteroid Regulation of CNS Development” by Mellon SH examines the role of neurosteroids in the development of the central nervous system (CNS). It focuses on how these steroids influence various developmental stages and processes within the CNS, highlighting their significance in neural growth and maturation. The research provides valuable insights into the complex mechanisms of CNS development and the potential impact of neurosteroids in this process.
For more detailed information: https://www.sciencedirect.com/science/article/pii/S016372580700109X
Petit GH, Tobin C, Krishnan K, et al. Pregnenolone sulfate and its enantiomer: differential modulation of memory in a spatial discrimination task using forebrain NMDA receptor deficient mice. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2011;21(2):211-215. doi:10.1016/j.euroneuro.2010.09.010.
Pregnenolone sulfate and its enantiomer: differential modulation of memory in a spatial discrimination task using forebrain NMDA receptor deficient mice
The study “Pregnenolone Sulfate and Its Enantiomer: Differential Modulation of Memory in a Spatial Discrimination Task Using Forebrain NMDA Receptor Deficient Mice” by Petit et al. investigates the effects of pregnenolone sulfate and its enantiomer on memory using mice with forebrain NMDA receptor deficiencies. This research is significant in understanding how these compounds might differentially influence memory processes, particularly in the context of NMDA receptor function.
For more detailed information: https://www.sciencedirect.com/science/article/pii/S0924977X10002142
Marx CE, Keefe RS, Buchanan RW, et al. Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2009;34(8):1885-1903. doi:10.1038/npp.2009.26.
Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia
The study “Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia” by Marx et al. evaluates the effects of pregnenolone on schizophrenia symptoms. It specifically examines whether pregnenolone can improve cognitive abilities and reduce negative symptoms in individuals with schizophrenia over 8 weeks. This research contributes to understanding the potential therapeutic uses of neurosteroids in treating schizophrenia.
For more detailed information: https://www.nature.com/articles/npp200926
Bu J, Zu H. Effects of pregnenolone intervention on the cholinergic system and synaptic protein 1 in aged rats. The International journal of neuroscience. 2014; 124(2):117-24.
Effects of pregnenolone intervention on the cholinergic system and synaptic protein 1 in aged rats
The study “Effects of Pregnenolone Intervention on the Cholinergic System and Synaptic Protein 1 in Aged Rats” by Bu and Zu investigates the impact of pregnenolone on the cholinergic system and synaptic protein 1 in elderly rats. This research is aimed at understanding how pregnenolone supplementation might affect these crucial components of the nervous system that are important for cognitive functions and are often altered during aging.
For more detailed information: https://www.tandfonline.com/doi/abs/10.3109/00207454.2013.824437
Bu J, Zu H. Effects of pregnenolone intervention on the cholinergic system and synaptic protein 1 in aged rats. The International journal of neuroscience. 2014; 124(2):117-24.
Effects of pregnenolone intervention on the cholinergic system and synaptic protein 1 in aged rats
The study “Effects of Pregnenolone Intervention on the Cholinergic System and Synaptic Protein 1 in Aged Rats” by Bu and Zu examines the impact of pregnenolone treatment on the cholinergic system and synaptic protein 1 in elderly rats. This research is significant in understanding how pregnenolone may influence cognitive-related processes in the aging brain.
For more detailed information: https://www.tandfonline.com/doi/abs/10.3109/00207454.2013.824437
Meieran SE, Reus VI, Webster R, Shafton R, Wolkowitz OM. Chronic pregnenolone effects in normal humans: attenuation of benzodiazepine-induced sedation. Psychoneuroendocrinology. 2004; 29(4):486-500.
Chronic pregnenolone effects in normal humans: attenuation of benzodiazepine-induced sedation
The study “Chronic Pregnenolone Effects in Normal Humans: Attenuation of Benzodiazepine-Induced Sedation” by Meieran et al. explores the impact of prolonged pregnenolone administration on benzodiazepine-induced sedation in humans. It investigates how pregnenolone, a neurosteroid, might affect the sedative action of benzodiazepines, which are commonly used for their calming effects. This research is important for understanding potential interactions between neurosteroids and benzodiazepines, especially in the context of their effects on the central nervous system.
For more detailed information: https://www.sciencedirect.com/science/article/pii/S0306453003000568
Darbra S, George O, Bouyer JJ, Piazza PV, Le Moal M, Mayo W. Sleep-wake states and cortical synchronization control by pregnenolone sulfate into the pedunculopontine nucleus. Journal of neuroscience research. 2004; 76(5):742-7.
Sleep-wake states and cortical synchronization control by pregnenolone sulfate into the pedunculopontine nucleus
The study “Sleep-wake States and Cortical Synchronization Control by Pregnenolone Sulfate into the Pedunculopontine Nucleus” by Darbra et al. investigates the effects of pregnenolone sulfate on sleep-wake states and cortical synchronization. It focuses on the influence of pregnenolone sulfate injections into the pedunculopontine nucleus, a brain area involved in sleep regulation. This research contributes to understanding the neurobiological mechanisms of sleep and the potential role of neurosteroids in modulating sleep-wake cycles.
For more detailed information: https://onlinelibrary.wiley.com/doi/abs/10.1002/jnr.20074
Darnaudéry M, Bouyer JJ, Pallarés M, Le Moal M, Mayo W. The promnesic neurosteroid pregnenolone sulfate increases paradoxical sleep in rats. Brain research. 1999; 818(2):492-8.
The promnesic neurosteroid pregnenolone sulfate increases paradoxical sleep in rats
The study “The Promnesic Neurosteroid Pregnenolone Sulfate Increases Paradoxical Sleep in Rats” by Darnaudéry et al. explores the effects of the neurosteroid pregnenolone sulfate on sleep, particularly focusing on paradoxical sleep (REM sleep) in rats. The research findings suggest that pregnenolone sulfate has a significant impact on increasing paradoxical sleep, offering insights into the potential role of neurosteroids in sleep regulation.
For more detailed information: https://www.sciencedirect.com/science/article/pii/S0006899398013389
Terán-Pérez G, Arana-Lechuga Y, Esqueda-León E, Santana-Miranda R, Rojas-Zamorano JÁ, Velázquez Moctezuma J. Steroid hormones and sleep regulation. Mini reviews in medicinal chemistry. 2012; 12(11):1040-8.
Steroid hormones and sleep regulation
The study “Steroid Hormones and Sleep Regulation” by Terán-Pérez et al. discusses how various steroid hormones, such as cortisol, melatonin, and sex hormones, influence sleep regulation. It focuses on the mechanisms by which these hormones affect sleep patterns and quality. This research is significant in understanding the complex relationship between hormonal regulation and sleep, which is critical for both physical and mental health.
For more detailed information: https://www.ingentaconnect.com/content/ben/mrmc/2012/00000012/00000011/art00002
Darbra S, George O, Bouyer JJ, Piazza PV, Le Moal M, Mayo W. Sleep-wake states and cortical synchronization control by pregnenolone sulfate into the pedunculopontine nucleus. Journal of neuroscience research. 2004; 76(5):742-7.
The study “Sleep-wake States and Cortical Synchronization Control by Pregnenolone Sulfate into the Pedunculopontine Nucleus” by Darbra et al. examines the influence of pregnenolone sulfate on sleep-wake states and cortical synchronization in rats. By focusing on the pedunculopontine nucleus, an area of the brain associated with sleep regulation, the study provides insights into how pregnenolone sulfate can modulate these physiological processes.
For more detailed information: https://onlinelibrary.wiley.com/doi/abs/10.1002/jnr.20074
Steiger A, Trachsel L, Guldner J, et al. Neurosteroid pregnenolone induces sleep-EEG changes in man compatible with inverse agonistic GABAA-receptor modulation. Brain research. 1993; 615(2):267-74.
Neurosteroid pregnenolone induces sleep-EEG changes in man compatible with inverse agonistic GABAA-receptor modulation
The study “Neurosteroid Pregnenolone Induces Sleep-EEG Changes in Man Compatible with Inverse Agonistic GABAA-Receptor Modulation” by Steiger et al. examines the effects of pregnenolone on sleep EEG patterns in humans. The research suggests that pregnenolone may act as an inverse agonist on GABA_A receptors, influencing sleep architecture. These findings contribute to understanding the neurobiological mechanisms of sleep regulation and the potential role of neurosteroids in modulating sleep.
For more detailed information: https://www.sciencedirect.com/science/article/pii/000689939390037N
Terán-Pérez G, Arana-Lechuga Y, Esqueda-León E, Santana-Miranda R, Rojas-Zamorano JÁ, Velázquez Moctezuma J. Steroid hormones and sleep regulation. Mini reviews in medicinal chemistry. 2012; 12(11):1040-8.
Steroid hormones and sleep regulation. Mini reviews in medicinal chemistry
The review article “Steroid Hormones and Sleep Regulation” by Terán-Pérez et al. discusses the influence of various steroid hormones, such as cortisol, estrogen, progesterone, and testosterone, on sleep regulation. It delves into the mechanisms by which these hormones impact sleep patterns and architecture, offering insights into the complex interplay between endocrine function and sleep physiology. This work contributes to the understanding of hormonal influences on sleep and potential implications for sleep disorders.
For more detailed information: https://www.ingentaconnect.com/content/ben/mrmc/2012/00000012/00000011/art00002
Terán-Pérez G, Arana-Lechuga Y, Esqueda-León E, Santana-Miranda R, Rojas-Zamorano JÁ, Velázquez Moctezuma J. Steroid hormones and sleep regulation. Mini reviews in medicinal chemistry. 2012; 12(11):1040-8.
Steroid hormones and sleep regulation
The review article “Steroid Hormones and Sleep Regulation” by Terán-Pérez et al. provides an in-depth analysis of the impact of various steroid hormones on sleep regulation. It covers the roles of hormones such as cortisol, estrogen, progesterone, and testosterone, examining how they influence different aspects of sleep patterns and architecture. This comprehensive review contributes significantly to understanding the complex relationship between endocrine functions and sleep physiology, shedding light on potential therapeutic approaches for sleep disorders linked to hormonal imbalances.
For more detailed information: https://www.ingentaconnect.com/content/ben/mrmc/2012/00000012/00000011/art00002
Carta MG, Bhat KM, Preti A. GABAergic neuroactive steroids: a new frontier in bipolar disorders? Behavioral and Brain Functions : BBF. 2012;8:61. doi:10.1186/1744-9081-8-61.
GABAergic neuroactive steroids: a new frontier in bipolar disorders? Behavioral and Brain Functions
The article “GABAergic Neuroactive Steroids: A New Frontier in Bipolar Disorders?” by Carta, Bhat, and Preti explores the potential role of GABAergic neuroactive steroids in the treatment of bipolar disorders. It discusses how these steroids could affect GABAergic transmission and thereby influence mood disorders. This research suggests a promising new direction for understanding and treating bipolar disorders, focusing on the modulation of neuroactive steroid levels.
For more detailed information: https://link.springer.com/article/10.1186/1744-9081-8-61
Fung LK, Libove RA, Phillips J, Haddad F, Hardan AY. Brief Report: An Open-Label Study of the Neurosteroid Pregnenolone in Adults with Autism Spectrum Disorder. Journal of autism and developmental disorders. 2014;44(11):2971-2977. doi:10.1007/s10803-014-2144-4.
An Open-Label Study of the Neurosteroid Pregnenolone in Adults with Autism Spectrum Disorder
The study “An Open-Label Study of the Neurosteroid Pregnenolone in Adults with Autism Spectrum Disorder” by Fung, Libove, Phillips, Haddad, and Hardan investigates the effects of pregnenolone treatment in adults with Autism Spectrum Disorder (ASD). This open-label study examines whether pregnenolone can improve certain symptoms associated with ASD. The findings contribute to the ongoing research on potential treatments for ASD.
For more detailed information: https://link.springer.com/article/10.1007/s10803-014-2144-4
Sripada RK, Marx CE, King AP, Rampton JC, Ho S, Liberzon I. Allopregnanolone Elevations Following Pregnenolone Administration are Associated with Enhanced Activation of Emotion Regulation Neurocircuits. Biological psychiatry. 2013;73(11):1045-1053. doi:10.1016/j.biopsych.2012.12.008.
Allopregnanolone Elevations Following Pregnenolone Administration are Associated with Enhanced Activation of Emotion Regulation Neurocircuits
The study “Allopregnanolone Elevations Following Pregnenolone Administration are Associated with Enhanced Activation of Emotion Regulation Neurocircuits” by Sripada et al. investigates the effects of pregnenolone on allopregnanolone levels and emotion regulation. It focuses on how this increase in allopregnanolone enhances the activation of neurocircuits involved in emotional regulation. This research provides insights into the neurobiological mechanisms of emotion regulation and the potential therapeutic uses of neurosteroids in psychiatric conditions
For more detailed information: https://www.sciencedirect.com/science/article/pii/S0006322312010931
Osuji IJ, Vera-Bolaños E, Carmody TJ, Brown ES. Pregnenolone for cognition and mood in dual diagnosis patients. Psychiatry research. 2010; 178(2):309-12.
Pregnenolone for cognition and mood in dual diagnosis patients
The study “Pregnenolone for Cognition and Mood in Dual Diagnosis Patients” by Osuji et al. assesses the effects of pregnenolone on cognitive function and mood in patients with dual diagnosis (psychiatric disorder and substance abuse). It aims to determine whether pregnenolone can improve cognitive deficits and mood symptoms in this population. This research contributes to the exploration of pregnenolone as a potential treatment option for cognitive and mood disorders in dual diagnosis patients.
For more detailed information: https://www.sciencedirect.com/science/article/pii/S0165178109003473
Bianchi M, Baulieu E-E. 3β-Methoxy-pregnenolone (MAP4343) as an innovative therapeutic approach for depressive disorders. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(5):1713-1718. doi:10.1073/pnas.1121485109.
3β-Methoxy-pregnenolone (MAP4343) as an innovative therapeutic approach for depressive disorders
The study “3β-Methoxy-pregnenolone (MAP4343) as an Innovative Therapeutic Approach for Depressive Disorders” by Bianchi and Baulieu investigates the antidepressant potential of MAP4343, a synthetic derivative of pregnenolone. This research explores MAP4343’s effectiveness in treating depressive symptoms, highlighting its potential as a novel therapeutic option for depression.
For more detailed information: https://www.pnas.org/doi/abs/10.1073/pnas.1121485109
Mellon SH. Neurosteroid regulation of CNS development. Pharmacology & therapeutics. 2007;116(1):107-124. doi:10.1016/j.pharmthera.2007.04.011.
Neurosteroid regulation of CNS development
The article “Neurosteroid Regulation of CNS Development” by Mellon SH explores the critical role of neurosteroids in the development of the central nervous system (CNS). It discusses how these substances regulate various aspects of CNS development, including neuronal differentiation, growth, and synaptic function. This research provides insights into the complex mechanisms of CNS maturation and the potential influence of neurosteroids on neurodevelopmental processes
For more detailed information: https://www.sciencedirect.com/science/article/pii/S016372580700109X
Brown ES, Park J, Marx CE, et al. A Randomized, Double-Blind, Placebo-Controlled Trial of Pregnenolone for Bipolar Depression. Neuropsychopharmacology. 2014;39(12):2867-2873. doi:10.1038/npp.2014.138.
Placebo-Controlled Trial of Pregnenolone for Bipolar Depression
The study “A Randomized, Double-Blind, Placebo-Controlled Trial of Pregnenolone for Bipolar Depression” by Brown et al. investigates the efficacy of pregnenolone as a treatment for bipolar depression. The trial aimed to assess the effects of this neurosteroid on depressive symptoms in individuals with bipolar disorder. This research provides valuable insights into potential new treatment options for bipolar depression.
For more detailed information: https://www.nature.com/articles/npp2014138
Daftary S, Yon JM, Choi EK, et al. Microtubule associated protein 2 in bipolar depression: Impact of pregnenolone. Journal of affective disorders. 2017; 218:49-52.
Microtubule associated protein 2 in bipolar depression: Impact of pregnenolone
The study “Microtubule Associated Protein 2 in Bipolar Depression: Impact of Pregnenolone” by Daftary et al. examines the effect of pregnenolone on Microtubule Associated Protein 2 (MAP2) in the context of bipolar depression. MAP2 is important for neuronal structure and function, and this study explores how pregnenolone, a neurosteroid, might influence it, potentially offering new insights into the treatment of bipolar depression.
For more detailed information: https://www.sciencedirect.com/science/article/pii/S0165032716318626
Barrot M, Vallée M, Gingras MA, Le Moal M, Mayo W, Piazza PV. The neurosteroid pregnenolone sulphate increases dopamine release and the dopaminergic response to morphine in the rat nucleus accumbens. The European journal of neuroscience. 1999; 11(10):3757-60.
The neurosteroid pregnenolone sulphate increases dopamine release and the dopaminergic response to morphine in the rat nucleus accumbens
The study “The Neurosteroid Pregnenolone Sulphate Increases Dopamine Release and the Dopaminergic Response to Morphine in the Rat Nucleus Accumbens” by Barrot et al. explores the effect of the neurosteroid pregnenolone sulphate on dopamine release in the rat nucleus accumbens. It particularly examines how this compound affects the dopaminergic response to morphine, providing insights into the interactions between neurosteroids and dopamine systems.
For more detailed information: https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1460-9568.1999.00816.x
Wong P, Chang CCR, Marx CE, Caron MG, Wetsel WC, Zhang X. Pregnenolone Rescues Schizophrenia-Like Behavior in Dopamine Transporter Knockout Mice. Hashimoto K, ed. PLoS ONE. 2012;7(12):e51455. doi:10.1371/journal.pone.0051455.
Pregnenolone Rescues Schizophrenia-Like Behavior in Dopamine Transporter Knockout Mice
The study “Pregnenolone Rescues Schizophrenia-Like Behavior in Dopamine Transporter Knockout Mice” by Wong et al. investigates the therapeutic potential of pregnenolone in alleviating schizophrenia-like behaviors in mice with dopamine transporter deficiencies. The findings indicate that pregnenolone can significantly mitigate these behaviors, suggesting its potential as a treatment for certain symptoms of schizophrenia.
For more detailed information: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0051455
Semeniuk T, Jhangri GS, Le Mellédo JM. Neuroactive steroid levels in patients with generalized anxiety disorder. The Journal of neuropsychiatry and clinical neurosciences. 2001; 13(3):396-8.
Neuroactive steroid levels in patients with generalized anxiety disorder
The study “Neuroactive Steroid Levels in Patients with Generalized Anxiety Disorder” by Semeniuk, Jhangri, and Le Mellédo examines the levels of neuroactive steroids in individuals with generalized anxiety disorder (GAD). It explores the relationship between these steroid levels and the presence of GAD, contributing to the understanding of the neurobiological aspects of anxiety disorders.
For more detailed information: https://neuro.psychiatryonline.org/doi/abs/10.1176/jnp.13.3.396
Grigoryev DN, Long BJ, Njar VC, Brodie AH. Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor. The Journal of steroid biochemistry and molecular biology. 2000; 75(1):1-10.
Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor
The study “Pregnenolone Stimulates LNCaP Prostate Cancer Cell Growth via the Mutated Androgen Receptor” by Grigoryev et al. explores how pregnenolone influences the growth of LNCaP prostate cancer cells that have a mutated androgen receptor. This research is significant as it contributes to understanding the role of neurosteroids like pregnenolone in prostate cancer cell proliferation, especially in the context of androgen receptor mutations
For more detailed information: https://www.sciencedirect.com/science/article/pii/S096007600000131X
Abul-Hajj YJ, Iverson R, Kiang DT. Metabolism of pregnenolone by human breast cancer. Evidence for 17 alpha-hydroxylase and 17,20-lyase. Steroids. 1979; 34(7):817-27.
Metabolism of pregnenolone by human breast cancer
The study “Metabolism of Pregnenolone by Human Breast Cancer: Evidence for 17 Alpha-Hydroxylase and 17,20-Lyase” by Abul-Hajj et al. investigates the metabolism of pregnenolone in human breast cancer. The research focuses on the presence and activity of enzymes like 17 alpha-hydroxylase and 17,20-lyase in breast cancer tissues, highlighting the complex interactions between steroids and breast cancer metabolism.
For more detailed information: https://www.sciencedirect.com/science/article/pii/0039128X79900941
Iqbal Choudhary M, Shahab Alam M, Atta-Ur-Rahman , et al. Pregnenolone derivatives as potential anticancer agents. Steroids. 2011; 76(14):1554-9.
Pregnenolone derivatives as potential anticancer agents
The study “Pregnenolone Derivatives as Potential Anticancer Agents” by Iqbal Choudhary, Shahab Alam, Atta-Ur-Rahman, et al., explores the potential of pregnenolone derivatives as anticancer compounds. It highlights the promise of these derivatives in cancer therapy, underscoring the need for further research to fully understand their therapeutic potential and mechanisms of action in cancer treatment.
For more detailed information: https://www.sciencedirect.com/science/article/pii/S0039128X11002844
Naylor J, Li J, Milligan CJ, et al. Pregnenolone sulphate- and cholesterol-regulated TRPM3 channels coupled to vascular smooth muscle secretion and contraction. Circulation research. 2010; 106(9):1507-15.
Pregnenolone sulphate- and cholesterol-regulated TRPM3 channels coupled to vascular smooth muscle secretion and contraction
The study “Pregnenolone Sulphate- and Cholesterol-Regulated TRPM3 Channels Coupled to Vascular Smooth Muscle Secretion and Contraction” by Naylor et al. investigates the regulatory role of pregnenolone sulphate and cholesterol on TRPM3 channels in vascular smooth muscle. It focuses on how these substances influence muscle contraction and secretion, contributing to understanding the mechanisms underlying blood vessel function and potential cardiovascular implications
For more detailed information: https://www.ahajournals.org/doi/abs/10.1161/CIRCRESAHA.110.219329
Tuckey RC, Atkinson HC. Pregnenolone synthesis from cholesterol and hydroxycholesterols by mitochondria from ovaries following the stimulation of immature rats with pregnant mare’s serum gonadotropin and human choriogonadotropin. European journal of biochemistry. 1989; 186(1-2):255-9.
Pregnenolone synthesis from cholesterol and hydroxycholesterols by mitochondria from ovaries following the stimulation of immature rats with pregnant mare’s serum gonadotropin and human choriogonadotropin
The study “Pregnenolone Synthesis from Cholesterol and Hydroxycholesterols by Mitochondria from Ovaries Following the Stimulation of Immature Rats with Pregnant Mare’s Serum Gonadotropin and Human Choriogonadotropin” by Tuckey and Atkinson examines how pregnenolone is synthesized from cholesterol in ovarian mitochondria. It focuses on the changes following stimulation with hormones in immature rats, contributing to our understanding of steroidogenesis in ovarian tissues.
For more detailed information: https://febs.onlinelibrary.wiley.com/doi/abs/10.1111/j.1432-1033.1989.tb15203.x
Burstein S, Gut M. Intermediates in the conversion of cholesterol to pregnenolone: kinetics and mechanism. Steroids. 1976; 28(1):115-31.
Intermediates in the conversion of cholesterol to pregnenolone
The study “Intermediates in the Conversion of Cholesterol to Pregnenolone: Kinetics and Mechanism” by Burstein and Gut investigates the biochemical process of converting cholesterol to pregnenolone. It focuses on understanding the intermediates and kinetic mechanisms involved in this crucial step in steroidogenesis. This research is significant for elucidating the pathways and reactions involved in steroid hormone production
For more detailed information: https://www.sciencedirect.com/science/article/pii/0039128X76901318
Ohta Y, Mitani F, Ishimura Y, Yanagibashi K, Kawamura M, Kawato S. Conversion of cholesterol to pregnenolone mobilizes cytochrome P-450 in the inner membrane of adrenocortical mitochondria: protein rotation study. Journal of biochemistry. 1990; 107(1):97-104.
Conversion of cholesterol to pregnenolone mobilizes cytochrome P-450 in the inner membrane of adrenocortical mitochondria
The study “Conversion of Cholesterol to Pregnenolone Mobilizes Cytochrome P-450 in the Inner Membrane of Adrenocortical Mitochondria: Protein Rotation Study” by Ohta et al. examines how the conversion of cholesterol to pregnenolone affects cytochrome P-450 in adrenocortical mitochondria. This research provides insights into the molecular dynamics of steroidogenesis, particularly the role of cytochrome P-450 in the inner mitochondrial membrane.
For more detailed information: https://www.jstage.jst.go.jp/article/biochemistry1922/107/1/107_1_97/_article/-char/ja/
Shikita M, Hall PF. The Stoichiometry of the Conversion of Cholesterol and Hydroxycholesterols to Pregnenolone (3β-Hydroxypregn-5-en-20-one) Catalysed by Adrenal Cytochrome P-450. Proceedings of the National Academy of Sciences of the United States of America. 1974;71(4):1441-1445.
The Stoichiometry of the Conversion of Cholesterol and Hydroxycholesterols to Pregnenolone (3β-Hydroxypregn-5-en-20-one) Catalysed by Adrenal Cytochrome P-450
The study “The Stoichiometry of the Conversion of Cholesterol and Hydroxycholesterols to Pregnenolone (3β-Hydroxypregn-5-en-20-one) Catalysed by Adrenal Cytochrome P-450” by Shikita and Hall PF investigates the enzymatic conversion process of cholesterol to pregnenolone in the adrenal gland, focusing on the role of cytochrome P-450 in this conversion. It provides detailed insights into the stoichiometry and biochemical pathways involved in steroidogenesis
For more detailed information: https://www.pnas.org/doi/abs/10.1073/pnas.71.4.1441
Provencher PH, Roy R, Bélanger A. Pregnenolone fatty acid esters incorporated into lipoproteins: substrates in adrenal steroidogenesis. Endocrinology. 1992; 130(5):2717-24.
Pregnenolone fatty acid esters incorporated into lipoproteins: substrates in adrenal steroidogenesis
The study “Pregnenolone Fatty Acid Esters Incorporated into Lipoproteins: Substrates in Adrenal Steroidogenesis” by Provencher, Roy, and Bélanger explores how pregnenolone fatty acid esters in lipoproteins function as substrates in adrenal steroidogenesis. This research highlights the role of these esters in the synthesis of steroid hormones, contributing to the understanding of the biochemical processes in the adrenal glands.
For more detailed information: https://academic.oup.com/endo/article-abstract/130/5/2717/3034454
Ritsner MS, Bawakny H, Kreinin A. Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial. Psychiatry and clinical neurosciences. 2014; 68(6):432-40.
Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial
The study “Pregnenolone Treatment Reduces Severity of Negative Symptoms in Recent-Onset Schizophrenia” by Ritsner et al. investigates the effects of pregnenolone as an add-on treatment in patients with recent-onset schizophrenia. Over an 8-week period, the double-blind, randomized trial found that pregnenolone supplementation significantly reduced the severity of negative symptoms associated with schizophrenia. This suggests potential therapeutic benefits of pregnenolone in managing certain symptoms of this disorder.
For more detailed information: https://onlinelibrary.wiley.com/doi/abs/10.1111/pcn.12150
Smith CC, Gibbs TT, Farb DH. Pregnenolone sulfate as a modulator of synaptic plasticity. Psychopharmacology. 2014;231(17):3537-3556. doi:10.1007/s00213-014-3643-x.
Pregnenolone sulfate as a modulator of synaptic plasticity
The study “Pregnenolone Sulfate as a Modulator of Synaptic Plasticity” by Smith et al. examines the role of pregnenolone sulfate, a neuroactive steroid, in modulating synaptic plasticity. This research delves into the mechanisms by which pregnenolone sulfate influences synaptic function, offering insights into its potential impact on cognitive processes and mental health disorders
For more detailed information: https://link.springer.com/article/10.1007/s00213-014-3643-x
Mellon SH. Neurosteroid regulation of CNS development. Pharmacology & therapeutics. 2007;116(1):107-124. doi:10.1016/j.pharmthera.2007.04.011.
Neurosteroid regulation of CNS development
The study “Neurosteroid Regulation of CNS Development” by Mellon SH focuses on how neurosteroids regulate the development of the central nervous system (CNS). It examines the roles of these steroids in neural growth, differentiation, and synaptic function, highlighting their significance in CNS maturation. This research is key to understanding the mechanisms of CNS development and the potential impact of neurosteroids in this process.
For more detailed information: https://www.sciencedirect.com/science/article/pii/S016372580700109X
Mellon SH. Neurosteroid regulation of CNS development. Pharmacology & therapeutics. 2007;116(1):107-124. doi:10.1016/j.pharmthera.2007.04.011.
Neurosteroid regulation of CNS development
The study “Neurosteroid Regulation of CNS Development” by Mellon SH explores the role of neurosteroids in the development of the central nervous system (CNS). It highlights how these steroids influence various developmental processes in the CNS, including neuronal growth, differentiation, and synaptic functionality. This research provides significant insights into the neurochemical mechanisms underpinning CNS development and the potential impact of neurosteroids in neurodevelopmental processes.
For more detailed information: https://www.sciencedirect.com/science/article/pii/S016372580700109X
Yang R, Zhou R, Chen L, et al. Pregnenolone sulfate enhances survival of adult-generated hippocampal granule cells via sustained presynaptic potentiation. Neuropharmacology. ; 60(2-3):529-41.
Pregnenolone sulfate enhances survival of adult-generated hippocampal granule cells via sustained presynaptic potentiation
The study “Pregnenolone Sulfate Enhances Survival of Adult-Generated Hippocampal Granule Cells via Sustained Presynaptic Potentiation” by Yang et al. examines how pregnenolone sulfate influences the survival of newly formed hippocampal granule cells. It suggests that this neurosteroid promotes cell survival through a mechanism involving sustained presynaptic potentiation, offering insights into neurogenesis and synaptic functionality.
For more detailed information: https://www.sciencedirect.com/science/article/pii/S0028390810003163
Weng JH, Liang MR, Chen CH, et al. Pregnenolone activates CLIP-170 to promote microtubule growth and cell migration. Nature chemical biology. 2013; 9(10):636-42.
Pregnenolone activates CLIP-170 to promote microtubule growth and cell migration
The study “Pregnenolone Activates CLIP-170 to Promote Microtubule Growth and Cell Migration” by Weng et al. investigates how pregnenolone, a neurosteroid, activates CLIP-170, a microtubule-associated protein. This activation leads to enhanced microtubule growth and cell migration, providing insights into the cellular and molecular mechanisms of pregnenolone’s actions.
For more detailed information: https://www.nature.com/articles/nchembio.1321
Veiga S, Garcia-Segura LM, Azcoitia I. Neuroprotection by the steroids pregnenolone and dehydroepiandrosterone is mediated by the enzyme aromatase. Journal of neurobiology. 2003; 56(4):398-406.
Neuroprotection by the steroids pregnenolone and dehydroepiandrosterone is mediated by the enzyme aromatase
The study “Neuroprotection by the Steroids Pregnenolone and Dehydroepiandrosterone is Mediated by the Enzyme Aromatase” by Veiga, Garcia-Segura, and Azcoitia explores how the neurosteroids pregnenolone and dehydroepiandrosterone (DHEA) offer neuroprotection. It specifically examines the role of the enzyme aromatase in this process, highlighting a potential mechanism for the neuroprotective effects of these steroids
For m
ore detailed information: https://onlinelibrary.wiley.com/doi/abs/10.1002/neu.10249
Shirakawa H, Katsuki H, Kume T, Kaneko S, Akaike A. Pregnenolone sulphate attenuates AMPA cytotoxicity on rat cortical neurons. The European journal of neuroscience. 2005; 21(9):2329-35.
Pregnenolone sulphate attenuates AMPA cytotoxicity on rat cortical neurons
The study “Pregnenolone Sulphate Attenuates AMPA Cytotoxicity on Rat Cortical Neurons” by Shirakawa et al. investigates the protective effects of pregnenolone sulphate against cytotoxicity induced by AMPA in rat cortical neurons. This research highlights the neuroprotective potential of pregnenolone sulphate in conditions characterized by excitotoxicity.
For more detailed information: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1460-9568.2005.04079.x
Ritsner MS, Bawakny H, Kreinin A. Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial. Psychiatry and clinical neurosciences. 2014; 68(6):432-40.
Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia
The study “Pregnenolone Treatment Reduces Severity of Negative Symptoms in Recent-Onset Schizophrenia” by Ritsner et al. focuses on evaluating the effects of pregnenolone as an adjunct treatment for recent-onset schizophrenia. Conducted over 8 weeks, this double-blind, randomized trial demonstrated that pregnenolone supplementation led to a significant reduction in the severity of negative symptoms associated with schizophrenia, suggesting its potential therapeutic benefits.
For more detailed information: https://onlinelibrary.wiley.com/doi/abs/10.1111/pcn.12150
Ritsner MS, Bawakny H, Kreinin A. Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial. Psychiatry and clinical neurosciences. 2014; 68(6):432-40.
Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial
The study “Pregnenolone Treatment Reduces Severity of Negative Symptoms in Recent-Onset Schizophrenia” by Ritsner et al. is a double-blind, randomized trial examining the effects of pregnenolone on negative symptoms in individuals with recent-onset schizophrenia. Conducted over 8 weeks, the study found that pregnenolone significantly reduced the severity of these symptoms, suggesting its potential as an adjunct treatment for schizophrenia.
For more detailed information: https://onlinelibrary.wiley.com/doi/abs/10.1111/pcn.12150
Weng JH, Chung BC. Nongenomic actions of neurosteroid pregnenolone and its metabolites. Steroids. 2016; 111:54-59.
Nongenomic actions of neurosteroid pregnenolone and its metabolites
The study “Nongenomic Actions of Neurosteroid Pregnenolone and Its Metabolites” by Weng and Chung BC discusses the rapid, non-genomic effects of the neurosteroid pregnenolone and its metabolites. It focuses on the impact of these substances on cellular signaling pathways, independent of gene expression regulation, highlighting their role in the nervous system’s functioning
For more detailed information: https://www.sciencedirect.com/science/article/pii/S0039128X16000180
Mellon SH. Neurosteroid regulation of CNS development. Pharmacology & therapeutics. 2007;116(1):107-124. doi:10.1016/j.pharmthera.2007.04.011.
Neurosteroid regulation of CNS development. Pharmacology & therapeutics.
The article “Neurosteroid Regulation of CNS Development” by Mellon SH focuses on the crucial role of neurosteroids in the development of the central nervous system (CNS). It highlights how these substances influence various developmental processes, such as neuronal growth and synaptic function, contributing to the intricate mechanisms of CNS maturation. This research sheds light on the potential impact of neurosteroids in neurodevelopmental processes.
For more detailed information: https://www.sciencedirect.com/science/article/pii/S016372580700109X
Petit GH, Tobin C, Krishnan K, et al. Pregnenolone sulfate and its enantiomer: differential modulation of memory in a spatial discrimination task using forebrain NMDA receptor deficient mice. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2011;21(2):211-215. doi:10.1016/j.euroneuro.2010.09.010.
Pregnenolone sulfate and its enantiomer
The study “Pregnenolone Sulfate and Its Enantiomer: Differential Modulation of Memory in a Spatial Discrimination Task Using Forebrain NMDA Receptor Deficient Mice” by Petit et al. explores the effects of pregnenolone sulfate and its enantiomer on memory, using mice with deficiencies in forebrain NMDA receptors. This research provides insights into the specific roles these compounds play in cognitive functions, particularly in the context of NMDA receptor function.
For more detailed information: https://www.sciencedirect.com/science/article/pii/S0924977X10002142
Bu J, Zu H. Effects of pregnenolone intervention on the cholinergic system and synaptic protein 1 in aged rats. The International journal of neuroscience. 2014; 124(2):117-24.
Effects of pregnenolone intervention on the cholinergic system and synaptic protein 1 in aged rats
The study “Effects of Pregnenolone Intervention on the Cholinergic System and Synaptic Protein 1 in Aged Rats” by Bu and Zu investigates the impact of pregnenolone on the cholinergic system and synaptic protein 1 in older rats. This research contributes to understanding how pregnenolone might influence cognitive-related processes in the aging brain.
For more detailed information: https://www.tandfonline.com/doi/abs/10.3109/00207454.2013.824437
Marx CE, Keefe RS, Buchanan RW, et al. Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2009;34(8):1885-1903. doi:10.1038/npp.2009.26.
Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia
The study “Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia” by Marx et al. evaluates the effectiveness of pregnenolone in treating cognitive and negative symptoms in schizophrenia. Conducted as a clinical trial, it examines pregnenolone’s potential as a therapeutic agent for these symptoms in individuals with schizophrenia.
For more detailed information: https://www.nature.com/articles/npp200926
Mellon SH. Neurosteroid regulation of CNS development. Pharmacology & therapeutics. 2007;116(1):107-124. doi:10.1016/j.pharmthera.2007.04.011.
Neurosteroid regulation of CNS development. Pharmacology & therapeutics
The article “Neurosteroid Regulation of CNS Development” by Mellon SH provides an in-depth review of the role neurosteroids play in the development of the central nervous system (CNS). It covers how these steroids affect various processes like neuronal growth, differentiation, and synaptic functioning, offering insights into their significant influence on CNS maturation. This review contributes to our understanding of neurosteroid mechanisms in neurodevelopmental processes.
For more detailed information: https://www.sciencedirect.com/science/article/pii/S016372580700109X
Petit GH, Tobin C, Krishnan K, et al. Pregnenolone sulfate and its enantiomer: differential modulation of memory in a spatial discrimination task using forebrain NMDA receptor deficient mice. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2011;21(2):211-215. doi:10.1016/j.euroneuro.2010.09.010.
Pregnenolone sulfate and its enantiomer
The study “Pregnenolone Sulfate and Its Enantiomer: Differential Modulation of Memory in a Spatial Discrimination Task Using Forebrain NMDA Receptor Deficient Mice” by Petit et al. investigates the effects of pregnenolone sulfate and its enantiomer on memory modulation using mice with a deficiency in forebrain NMDA receptors. This research provides insights into how these compounds influence cognitive functions, especially in the context of NMDA receptor functionality.
For more detailed information: https://www.sciencedirect.com/science/article/pii/S0924977X10002142
Marx CE, Keefe RS, Buchanan RW, et al. Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2009;34(8):1885-1903. doi:10.1038/npp.2009.26.
Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia
The study “Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia” by Marx et al. is a clinical trial that explores the effectiveness of pregnenolone in treating cognitive and negative symptoms associated with schizophrenia. The research evaluates the potential of pregnenolone as a therapeutic option for improving these specific aspects of schizophrenia.
For further details visit https://pubmed.ncbi.nlm.nih.gov/19339966/
Steiger A, Trachsel L, Guldner J, et al. Neurosteroid pregnenolone induces sleep-EEG changes in man compatible with inverse agonistic GABAA-receptor modulation. Brain research. 1993; 615(2):267-74.
Neurosteroid pregnenolone induces sleep-EEG changes in man compatible with inverse agonistic GABAA-receptor modulation
The study “Neurosteroid Pregnenolone Induces Sleep-EEG Changes in Man Compatible with Inverse Agonistic GABAA-Receptor Modulation” by Steiger et al. explores the effects of the neurosteroid pregnenolone on sleep electroencephalogram (EEG) patterns in humans. It suggests that pregnenolone may act as an inverse agonist on GABA_A receptors, influencing sleep architecture and indicating its potential role in sleep modulation.
For further details visit https://www.sciencedirect.com/science/article/pii/000689939390037N
Darbra S, George O, Bouyer JJ, Piazza PV, Le Moal M, Mayo W. Sleep-wake states and cortical synchronization control by pregnenolone sulfate into the pedunculopontine nucleus. Journal of neuroscience research. 2004; 76(5):742-7.
Sleep-wake states and cortical synchronization control by pregnenolone sulfate into the pedunculopontine nucleus
The study “Sleep-wake States and Cortical Synchronization Control by Pregnenolone Sulfate into the Pedunculopontine Nucleus” by Darbra et al. examines the influence of pregnenolone sulfate on sleep-wake states and cortical synchronization in rats. By focusing on the pedunculopontine nucleus, an area of the brain associated with sleep regulation, the study provides insights into how pregnenolone sulfate can modulate these physiological processes.
For further details visit https://www.sciencedirect.com/science/article/pii/000689939390037N
Terán-Pérez G, Arana-Lechuga Y, Esqueda-León E, Santana-Miranda R, Rojas-Zamorano JÁ, Velázquez Moctezuma J. Steroid hormones and sleep regulation. Mini reviews in medicinal chemistry. 2012; 12(11):1040-8.
Steroid hormones and sleep regulation. Mini reviews in medicinal chemistry
The review article “Steroid Hormones and Sleep Regulation” by Terán-Pérez et al. discusses the impact of various steroid hormones, including cortisol, melatonin, and sex hormones, on sleep regulation. It delves into how these hormones affect different aspects of sleep, including sleep patterns and architecture. This comprehensive review offers insights into the complex interplay between endocrine functions and sleep physiology.
For further details visit https://www.ingentaconnect.com/content/ben/mrmc/2012/00000012/00000011/art00002
Steiger A, Trachsel L, Guldner J, et al. Neurosteroid pregnenolone induces sleep-EEG changes in man compatible with inverse agonistic GABAA-receptor modulation. Brain research. 1993; 615(2):267-74.
Neurosteroid pregnenolone induces sleep-EEG changes in man compatible with inverse agonistic GABAA-receptor modulation
The study “Neurosteroid Pregnenolone Induces Sleep-EEG Changes in Man Compatible with Inverse Agonistic GABAA-Receptor Modulation” by Steiger et al. investigates the impact of pregnenolone on sleep patterns, particularly in relation to its effects on GABAA receptors in the brain. The research suggests that pregnenolone may act as an inverse agonist at these receptors, leading to changes in sleep electroencephalogram (EEG) patterns. This study contributes to understanding the neurobiological mechanisms underlying sleep regulation.
For further details visit https://www.sciencedirect.com/science/article/pii/000689939390037N
Ritsner MS, Bawakny H, Kreinin A. Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial. Psychiatry and clinical neurosciences. 2014; 68(6):432-40.
In the study titled “Pregnenolone Treatment Reduces Severity of Negative Symptoms in Recent-Onset Schizophrenia,” Ritsner et al. conducted an 8-week, double-blind, randomized trial involving individuals with recent-onset schizophrenia. The research investigated the effects of pregnenolone treatment as an add-on therapy. The results indicated that pregnenolone reduced the severity of negative symptoms in schizophrenia patients, suggesting its potential as a therapeutic option. This study was published in the journal Psychiatry and Clinical Neurosciences in 2014.
For further details visit https://onlinelibrary.wiley.com/doi/abs/10.1111/pcn.12150
Marx CE, Bradford DW, Hamer RM, et al. Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence. Neuroscience. 2011; 191:78-90.
Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence
The study “Pregnenolone as a Novel Therapeutic Candidate in Schizophrenia” by Marx et al. explores the potential of pregnenolone as a therapeutic option for schizophrenia. This review discusses emerging preclinical and clinical evidence supporting pregnenolone’s role in schizophrenia treatment. The findings suggest that pregnenolone may have a positive impact on cognitive and negative symptoms of schizophrenia, highlighting its potential as a novel therapeutic candidate. This review was published in the journal Neuroscience in 2011.
For further details visit https://www.sciencedirect.com/science/article/pii/S030645221100786X
Ritsner MS, Bawakny H, Kreinin A. Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial. Psychiatry and clinical neurosciences. 2014; 68(6):432-40.
Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia
In the study “Pregnenolone Treatment Reduces Severity of Negative Symptoms in Recent-Onset Schizophrenia,” conducted by Ritsner et al., an 8-week double-blind, randomized trial investigated the effects of pregnenolone as an add-on treatment for recent-onset schizophrenia. The results indicated that pregnenolone reduced the severity of negative symptoms in patients with schizophrenia, suggesting its potential as a supplementary therapy for improving symptomatology in this population. The study was published in Psychiatry and Clinical Neurosciences in 2014.
For further details visit https://onlinelibrary.wiley.com/doi/abs/10.1111/pcn.12150
Wong P, Sze Y, Chang CCR, Lee J, Zhang X. Pregnenolone sulfate normalizes schizophrenia-like behaviors in dopamine transporter knockout mice through the AKT/GSK3β pathway. Translational Psychiatry. 2015;5(3):e528-. doi:10.1038/tp.2015.21.
Pregnenolone sulfate normalizes schizophrenia-like behaviors in dopamine transporter knockout mice through the AKT/GSK3β pathway.
The study “Pregnenolone Sulfate Normalizes Schizophrenia-Like Behaviors in Dopamine Transporter Knockout Mice” by Wong et al. explored the effects of pregnenolone sulfate on schizophrenia-like behaviors in mice lacking the dopamine transporter. The results suggested that pregnenolone sulfate could alleviate these behaviors through the AKT/GSK3β pathway. This research, published in Translational Psychiatry in 2015, highlights the potential therapeutic role of pregnenolone sulfate in schizophrenia-related symptoms.
For further details visit https://www.nature.com/articles/tp201521
Carta MG, Bhat KM, Preti A. GABAergic neuroactive steroids: a new frontier in bipolar disorders? Behavioral and Brain Functions : BBF. 2012;8:61. doi:10.1186/1744-9081-8-61.
GABAergic neuroactive steroids: a new frontier in bipolar disorders?
The article “GABAergic Neuroactive Steroids: A New Frontier in Bipolar Disorders?” by Carta, Bhat, and Preti explores the potential role of GABAergic neuroactive steroids in the treatment of bipolar disorders. It discusses how these steroids could affect GABAergic transmission and thereby influence mood disorders. This research suggests a promising new direction for understanding and treating bipolar disorders, focusing on the modulation of neuroactive steroid levels.
For further details visit https://link.springer.com/article/10.1186/1744-9081-8-61
Miller MN, Miller BE. Premenstrual exacerbations of mood disorders. Psychopharmacol Bull. 2001;35(3):135–149.
Premenstrual exacerbations of mood disorders
The article “Premenstrual Exacerbations of Mood Disorders” by Miller and Miller, published in Psychopharmacology Bulletin in 2001, discusses the impact of the menstrual cycle on mood disorders in women. It explores the premenstrual exacerbation of conditions like depression and bipolar disorder, highlighting hormonal fluctuations as potential triggers. The article provides insights into the complex relationship between the menstrual cycle and mood disorders, emphasizing the need for further research and tailored treatment approaches for affected individuals
For further details visit https://europepmc.org/article/med/12397883
Bessa JM, Ferreira D, Melo I, Marques F, Cerqueira JJ, Palha JA, Almeida OF, Sousa N. The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling. Mol Psychiatry. 2009;14(8):764–773. doi: 10.1038/mp.2008.119. 739.
The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling. Mol Psychiatry
The study by Bessa et al. (2009) titled “The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling” suggests that the mood-enhancing effects of antidepressants are not solely dependent on the generation of new neurons (neurogenesis) but are instead linked to structural changes in existing neurons. The research challenges the conventional belief that neurogenesis is the primary mechanism of action for antidepressants and highlights the importance of neuronal remodeling in improving mood. This finding has implications for understanding the therapeutic mechanisms of antidepressant medications.
For further details visit https://www.nature.com/articles/mp2008119
Fung LK, Libove RA, Phillips J, Haddad F, Hardan AY. Brief Report: An Open-Label Study of the Neurosteroid Pregnenolone in Adults with Autism Spectrum Disorder. Journal of autism and developmental disorders. 2014;44(11):2971-2977. doi:10.1007/s10803-014-2144-4.
An Open-Label Study of the Neurosteroid Pregnenolone in Adults with Autism Spectrum Disorder
In the study by Fung et al. (2014), titled “An Open-Label Study of the Neurosteroid Pregnenolone in Adults with Autism Spectrum Disorder,” the researchers investigated the effects of pregnenolone in adults with autism spectrum disorder (ASD). Pregnenolone is a neurosteroid with potential neuromodulatory properties. The study found some improvements in behavioral symptoms associated with ASD following pregnenolone treatment, suggesting that further research into the potential therapeutic role of neurosteroids in ASD is warranted. However, this was an open-label study with a small sample size, and more rigorous clinical trials are needed to confirm these findings.
For further details visit https://link.springer.com/article/10.1007/s10803-014-2144-4
Sripada RK, Marx CE, King AP, Rampton JC, Ho S, Liberzon I. Allopregnanolone Elevations Following Pregnenolone Administration are Associated with Enhanced Activation of Emotion Regulation Neurocircuits. Biological psychiatry. 2013;73(11):1045-1053. doi:10.1016/j.biopsych.2012.12.008.
Allopregnanolone Elevations Following Pregnenolone Administration are Associated with Enhanced Activation of Emotion Regulation Neurocircuits.
In the study by Sripada et al. (2013), titled “Allopregnanolone Elevations Following Pregnenolone Administration are Associated with Enhanced Activation of Emotion Regulation Neurocircuits,” the researchers investigated the effects of pregnenolone administration on brain circuits involved in emotion regulation. They found that pregnenolone led to increased levels of allopregnanolone, a neurosteroid with known effects on mood regulation. These elevations in allopregnanolone were associated with enhanced activation of brain circuits involved in emotion regulation. This study suggests a potential role for pregnenolone in modulating emotional processes and may have implications for mood disorders.
For further details visit https://www.sciencedirect.com/science/article/pii/S0006322312010931
Osuji IJ, Vera-Bolaños E, Carmody TJ, Brown ES. Pregnenolone for cognition and mood in dual diagnosis patients. Psychiatry research. 2010; 178(2):309-12.
Pregnenolone for cognition and mood in dual diagnosis patients
The study by Osuji et al. (2010) titled “Pregnenolone for cognition and mood in dual diagnosis patients” investigated the potential benefits of pregnenolone supplementation on cognition and mood in individuals with dual diagnoses, including substance use and psychiatric disorders. The findings suggested that pregnenolone did not significantly improve cognitive function or mood in this population. While pregnenolone has shown promise in some studies for mood-related conditions, this particular study did not provide strong evidence for its efficacy in dual diagnosis patients.
For further details visit https://www.sciencedirect.com/science/article/pii/S0165178109003473
Brown ES, Park J, Marx CE, et al. A Randomized, Double-Blind, Placebo-Controlled Trial of Pregnenolone for Bipolar Depression. Neuropsychopharmacology. 2014;39(12):2867-2873. doi:10.1038/npp.2014.138.
A Randomized, Double-Blind, Placebo-Controlled Trial of Pregnenolone for Bipolar Depression.
The study conducted by Brown et al. (2014) titled “A Randomized, Double-Blind, Placebo-Controlled Trial of Pregnenolone for Bipolar Depression” aimed to assess the efficacy of pregnenolone as a treatment for bipolar depression. In this randomized controlled trial, pregnenolone did not demonstrate a significant benefit over the placebo in improving depressive symptoms in individuals with bipolar disorder. The study’s findings did not support the use of pregnenolone as a standalone treatment for bipolar depression.
For further details visit https://www.nature.com/articles/npp2014138
Carta MG, Bhat KM, Preti A. GABAergic neuroactive steroids: a new frontier in bipolar disorders. Behav Brain Funct. 2012;8:61.
GABAergic neuroactive steroids: a new frontier in bipolar disorders
The paper by Carta et al. (2012) explores the role of GABAergic neuroactive steroids in bipolar disorders. It highlights the potential significance of these steroids in the pathophysiology and treatment of bipolar disorder. GABAergic neuroactive steroids have been found to influence mood regulation and may represent a novel avenue for therapeutic interventions in bipolar disorders. The review discusses the neurobiological mechanisms underlying their effects and suggests that targeting these steroids could have therapeutic implications for bipolar disorder management.
For further details visit https://link.springer.com/article/10.1186/1744-9081-8-61
Bianchi M, Baulieu E-E. 3β-Methoxy-pregnenolone (MAP4343) as an innovative therapeutic approach for depressive disorders. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(5):1713-1718. doi:10.1073/pnas.1121485109.
3β-Methoxy-pregnenolone (MAP4343) as an innovative therapeutic approach for depressive disorders
The paper by Bianchi and Baulieu (2012) introduces 3β-Methoxy-pregnenolone (MAP4343) as a potential innovative therapeutic approach for depressive disorders. MAP4343 is explored as a novel antidepressant that targets specific receptors in the brain. The study discusses the neurobiological mechanisms underlying its antidepressant effects and presents it as a promising candidate for further research and development in the treatment of depression.
For further details visit https://www.pnas.org/doi/abs/10.1073/pnas.1121485109
Mellon SH. Neurosteroid regulation of CNS development. Pharmacology & therapeutics. 2007;116(1):107-124. doi:10.1016/j.pharmthera.2007.04.011.
Neurosteroid regulation of CNS development. Pharmacology & therapeutics
Mellon’s 2007 review in “Pharmacology & Therapeutics” discusses the role of neurosteroids in central nervous system (CNS) development. It highlights how neurosteroids, such as pregnenolone, play crucial roles in neural functions, including neuroprotection, myelination, and neurotransmission. The review emphasizes the significance of understanding neurosteroid actions in CNS development, which has implications for neurodevelopmental disorders and potential therapeutic interventions.
For further details visit https://www.sciencedirect.com/science/article/pii/S016372580700109X
Semeniuk T, Jhangri GS, Le Mellédo JM. Neuroactive steroid levels in patients with generalized anxiety disorder. The Journal of neuropsychiatry and clinical neurosciences. 2001; 13(3):396-8.
Neuroactive steroid levels in patients with generalized anxiety disorder.
The study by Semeniuk et al. in the “Journal of Neuropsychiatry and Clinical Neurosciences” in 2001 investigated neuroactive steroid levels in patients with generalized anxiety disorder (GAD). It found alterations in the levels of certain neuroactive steroids in individuals with GAD, suggesting a potential role for these steroids in the pathophysiology of anxiety disorders. However, the study’s findings were preliminary, and further research is needed to fully understand the relationship between neuroactive steroids and anxiety disorders.
For further details visit https://neuro.psychiatryonline.org/doi/abs/10.1176/jnp.13.3.396
Espallergues J, Mamiya T, Vallee M, Koseki T, Nabeshima T, Temsamani J, et al. The antidepressant-like effects of the 3beta-hydroxysteroid dehydrogenase inhibitor trilostane in mice is related to changes in neuroactive steroid and monoamine levels. Neuropharmacology. 2012;62:492–502.
The antidepressant-like effects of the 3beta-hydroxysteroid dehydrogenase inhibitor trilostane in mice is related to changes in neuroactive steroid and monoamine levels
The study by Espallergues et al. in “Neuropharmacology” in 2012 investigated the antidepressant-like effects of the 3β-hydroxysteroid dehydrogenase inhibitor trilostane in mice. The research found that trilostane led to changes in neuroactive steroid and monoamine levels, which may be related to its antidepressant-like effects. These findings suggest a potential role for neuroactive steroids in the mechanisms underlying depression and the antidepressant actions of trilostane. Further research is needed to explore this relationship in more detail.
For further details visit https://www.sciencedirect.com/science/article/pii/S0028390811003996
Nothdurfter C, Rupprecht R, Rammes G. Recent developments in potential anxiolytic agents targeting GABAA/BzR complex or the translocator protein (18 kDa) (TSPO) Curr Top Med Chem. 2012;12:360–370.
Recent developments in potential anxiolytic agents targeting GABAA/BzR complex or the translocator protein (18 kDa) (TSPO) Curr Top Med Chem.
The paper by Nothdurfter et al. in “Current Topics in Medicinal Chemistry” from 2012 discusses recent developments in potential anxiolytic (anti-anxiety) agents targeting the GABAA/BzR complex or the translocator protein (18 kDa) (TSPO). It explores the pharmacological mechanisms and potential therapeutic applications of these agents in managing anxiety disorders. The review provides insights into the ongoing research efforts to develop novel anxiolytic compounds targeting these molecular targets.
For further details visit https://www.ingentaconnect.com/content/ben/ctmc/2012/00000012/00000004/art00010
George MS, Guidotti A, Rubinow D, Pan B, Mikalauskas K, Post RM. CSF neuroactive steroids in affective disorders: pregnenolone, progesterone, and DBI. Biol Psychiatry. 1994;35:775–780.
CSF neuroactive steroids in affective disorders
In the study by George et al. published in “Biological Psychiatry” in 1994, cerebrospinal fluid (CSF) levels of neuroactive steroids, including pregnenolone, progesterone, and diazepam-binding inhibitor (DBI), were investigated in individuals with affective disorders. The research aimed to understand the potential role of these neuroactive steroids in mood disorders. The findings suggested alterations in the levels of these steroids in individuals with affective disorders, pointing to their possible involvement in the pathophysiology of mood disorders.
For further details visit https://www.sciencedirect.com/science/article/pii/0006322394911398
Sripada RK, Marx CE, King AP, Rampton JC, Ho S, Liberzon I. Allopregnanolone Elevations Following Pregnenolone Administration are Associated with Enhanced Activation of Emotion Regulation Neurocircuits. Biological psychiatry. 2013;73(11):1045-1053. doi:10.1016/j.biopsych.2012.12.008.
Allopregnanolone Elevations Following Pregnenolone Administration are Associated with Enhanced Activation of Emotion Regulation Neurocircuits
In the study by Sripada et al. published in “Biological Psychiatry” in 2013, the researchers investigated the effects of pregnenolone administration on allopregnanolone levels and emotion regulation neurocircuits. They found that elevations in allopregnanolone following pregnenolone administration were associated with enhanced activation of emotion regulation neurocircuits. This suggests that pregnenolone may have a role in modulating emotional processing and potentially be beneficial in conditions involving emotional dysregulation.
For further details visit https://www.sciencedirect.com/science/article/pii/S0006322312010931
Fung LK, Libove RA, Phillips J, Haddad F, Hardan AY. Brief Report: An Open-Label Study of the Neurosteroid Pregnenolone in Adults with Autism Spectrum Disorder. Journal of autism and developmental disorders. 2014;44(11):2971-2977. doi:10.1007/s10803-014-2144-4.
Brief Report: An Open-Label Study of the Neurosteroid Pregnenolone in Adults with Autism Spectrum Disorder
In the open-label study conducted by Fung et al. and published in the “Journal of Autism and Developmental Disorders” in 2014, the researchers investigated the effects of pregnenolone in adults with Autism Spectrum Disorder (ASD). Pregnenolone administration was associated with improvements in irritability, lethargy, and social relatedness in some individuals with ASD. While the study showed some promising results, it’s important to note that the study had limitations, including a small sample size and the absence of a control group.
For further details visit https://link.springer.com/article/10.1007/s10803-014-2144-4
Turkmen S, Backstrom T, Wahlstrom G, Andreen L, Johansson I-M. Tolerance to allopregnanolone with focus on the GABA-A receptor. British Journal of Pharmacology. 2011;162(2):311-327. doi:10.1111/j.1476-5381.2010.01059.x.
Tolerance to allopregnanolone with focus on the GABA-A receptor
The study by Turkmen et al. in the “British Journal of Pharmacology” (2011) investigated the development of tolerance to allopregnanolone, a neuroactive steroid that affects the GABA-A receptor. The research focused on the effects of repeated allopregnanolone exposure on GABA-A receptor function. The study found that tolerance to the sedative and anti-seizure effects of allopregnanolone developed, suggesting that the GABA-A receptor system can adapt to prolonged exposure to this neuroactive steroid. This research has implications for understanding the neurobiological mechanisms underlying the effects of allopregnanolone and its potential therapeutic applications.
For further details visit https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/j.1476-5381.2010.01059.x
Dávola ME, Mazaira GI, Galigniana MD, Alché LE, Ramírez JA, Barquero AA. Synthetic pregnenolone derivatives as antiviral agents against acyclovir-resistant isolates of Herpes Simplex Virus Type 1. Antiviral research. 2015; 122:55-63.
Synthetic pregnenolone derivatives as antiviral agents against acyclovir-resistant isolates of Herpes Simplex Virus Type 1
The study by Dávola et al. in “Antiviral Research” (2015) investigated synthetic pregnenolone derivatives as potential antiviral agents against acyclovir-resistant isolates of Herpes Simplex Virus Type 1 (HSV-1). The research aimed to identify compounds that could effectively inhibit the growth of HSV-1 strains resistant to acyclovir, a commonly used antiviral drug. The study found that certain synthetic pregnenolone derivatives exhibited antiviral activity against acyclovir-resistant HSV-1 isolates, suggesting their potential as alternative treatments for herpes infections that do not respond to acyclovir.
For further details visit https://www.sciencedirect.com/science/article/pii/S0166354215001886
Mahata B, Zhang X, Kolodziejczyk AA, et al. Single-Cell RNA Sequencing Reveals T Helper Cells Synthesizing Steroids De Novo to Contribute to Immune Homeostasis. Cell Reports. 2014;7(4):1130-1142. doi:10.1016/j.celrep.2014.04.011.
Single-Cell RNA Sequencing Reveals T Helper Cells Synthesizing Steroids De Novo to Contribute to Immune Homeostasis
The study by Mahata et al. in “Cell Reports” (2014) used single-cell RNA sequencing to investigate T helper cells that synthesize steroids de novo. This research revealed that a subset of T helper cells can produce steroids, which was previously unrecognized. These steroid-producing T cells play a role in immune homeostasis, potentially influencing the immune system’s response to various challenges. This discovery sheds light on a novel aspect of immune regulation and highlights the complexity of immune cell functions.
For further details visit https://www.cell.com/cell-reports/pdf/S2211-1247(14)00298-8.pdf
Morfin R, Courchay G. Pregnenolone and dehydroepiandrosterone as precursors of native 7-hydroxylated metabolites which increase the immune response in mice. The Journal of steroid biochemistry and molecular biology. 1994; 50(1-2):91-100.
Pregnenolone and dehydroepiandrosterone as precursors of native 7-hydroxylated metabolites which increase the immune response in mice
The study by Morfin and Courchay in “The Journal of Steroid Biochemistry and Molecular Biology” (1994) explored the role of pregnenolone and dehydroepiandrosterone (DHEA) as precursors of native 7-hydroxylated metabolites. These metabolites were found to enhance the immune response in mice. The research suggests that pregnenolone and DHEA may have immunomodulatory effects through the production of specific metabolites, highlighting their potential importance in immune function regulation.
For further details visit https://www.sciencedirect.com/science/article/pii/0960076094901767
Chen CC, Parker CR. Adrenal androgens and the immune system. Seminars in reproductive medicine. 2004; 22(4):369-77.
Adrenal androgens and the immune system
The study by Chen and Parker in “Seminars in Reproductive Medicine” (2004) explores the relationship between adrenal androgens and the immune system. It discusses how adrenal androgens, such as dehydroepiandrosterone (DHEA) and its sulfate form (DHEA-S), play a role in modulating immune function. These androgens are known to have immunomodulatory effects, affecting various aspects of the immune response. The review provides insights into the complex interplay between adrenal androgens and immune system regulation, highlighting their potential significance in immune-related disorders and therapies.
For further details visit https://www.thieme-connect.com/products/ejournals/html/10.1055/s-2004-861553
Slominski A, Zbytek B, Nikolakis G, et al. Steroidogenesis in the skin: implications for local immune functions. The Journal of steroid biochemistry and molecular biology. 2013;137:107-123. doi:10.1016/j.jsbmb.2013.02.006.
Steroidogenesis in the skin: implications for local immune functions
The article by Slominski et al. in “The Journal of Steroid Biochemistry and Molecular Biology” (2013) delves into the concept of steroidogenesis within the skin and its implications for local immune functions. It explores how the skin, often considered an endocrine organ, can produce steroids like cortisol, DHEA, and their precursors. These locally produced steroids play a role in regulating immune responses within the skin, impacting various immune cells and processes. Understanding skin-based steroidogenesis is crucial for comprehending the skin’s multifaceted roles in both endocrine and immune functions.
For further details visit https://research-repository.uwa.edu.au/en/publications/steroidogenesis-in-the-skin-implications-for-local-immune-functio
Rezvani AH, Levin ED. Assessment of pregnenolone effects on alcohol intake and preference in male alcohol preferring (P) rats. European journal of pharmacology. 2014; 740:53-7.
Assessment of pregnenolone effects on alcohol intake and preference in male alcohol preferring (P) rats
The study by Rezvani and Levin in the “European Journal of Pharmacology” (2014) investigated the effects of pregnenolone on alcohol intake and preference in male alcohol-preferring (P) rats. Pregnenolone is a neurosteroid that was explored for its potential to modulate alcohol consumption. The research found that pregnenolone reduced alcohol intake and preference in these rats. This suggests that pregnenolone may have a role in regulating alcohol consumption and could be relevant for understanding alcohol use disorders.
For further details visit https://www.sciencedirect.com/science/article/pii/S0014299914005214
Besheer J, Lindsay TG, O’Buckley TK, Hodge CW, Morrow AL. Pregnenolone and ganaxolone reduce operant ethanol self-administration in alcohol-preferring P rats. Alcoholism, clinical and experimental research. 2010;34(12):2044-2052. doi:10.1111/j.1530-0277.2010.01300.x.
Pregnenolone and ganaxolone reduce operant ethanol self-administration in alcohol-preferring P rats
In a study published in “Alcoholism, Clinical and Experimental Research” in 2010, Besheer and colleagues investigated the effects of pregnenolone and ganaxolone on operant ethanol self-administration in alcohol-preferring P rats. Both pregnenolone and ganaxolone were found to reduce the rats’ operant ethanol self-administration, suggesting that these neurosteroids have the potential to modulate alcohol consumption, which is relevant for understanding alcohol use disorders. This study provides further evidence of the role of neurosteroids in alcohol-related behaviors.
For further details visit https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1530-0277.2010.01300.x
Xiao X, Chen L, Ouyang Y, et al. Pregnenolone, a cholesterol metabolite, induces glioma cell apoptosis via activating extrinsic and intrinsic apoptotic pathways. Oncology Letters. 2014;8(2):645-650. doi:10.3892/ol.2014.2147.
Pregnenolone, a cholesterol metabolite, induces glioma cell apoptosis via activating extrinsic and intrinsic apoptotic pathways
In a study published in “Oncology Letters” in 2014, Xiao and colleagues investigated the effects of pregnenolone, a cholesterol metabolite, on glioma cell apoptosis. They found that pregnenolone induced apoptosis in glioma cells through the activation of both extrinsic and intrinsic apoptotic pathways. This research suggests a potential role for pregnenolone in the development of therapies for glioma, a type of brain tumor.
For further details visit https://www.spandidos-publications.com/ol/8/2/645
Iqbal Choudhary M, Shahab Alam M, Atta-Ur-Rahman , et al. Pregnenolone derivatives as potential anticancer agents. Steroids. 2011; 76(14):1554-9.
Pregnenolone derivatives as potential anticancer agents
The study published in “Steroids” in 2011 explored pregnenolone derivatives as potential anticancer agents. These derivatives were investigated for their potential to inhibit cancer cell growth and induce apoptosis. The research aimed to identify new compounds that could be used in the development of anticancer therapies.
For further details visit https://www.sciencedirect.com/science/article/pii/S0039128X11002844
Ramos G, Loperena Y, Ortiz G, et al. The addition of a pregnenolone pendant group enhances the anticancer properties of titanocene dichloride in a mcf-7 xenograft model. Anticancer research. 2014; 34(4):1609-15.
The addition of a pregnenolone pendant group enhances the anticancer properties of titanocene dichloride in a mcf-7 xenograft model
The study in “Anticancer Research” from 2014 investigated the anticancer properties of titanocene dichloride, a potential chemotherapy agent. The addition of a pregnenolone pendant group to titanocene dichloride enhanced its anticancer efficacy in a MCF-7 xenograft model. This modification improved the compound’s ability to inhibit tumor growth, making it a promising candidate for further development in cancer treatment.
For further details visit https://ar.iiarjournals.org/content/34/4/1609.short
Vallée M, Vitiello S, Bellocchio L, et al. Pregnenolone Can Protect the Brain from Cannabis Intoxication. Science (New York, NY). 2014;343(6166):94-98. doi:10.1126/science.1243985.
Pregnenolone Can Protect the Brain from Cannabis Intoxication
The study in “Science” from 2014 demonstrated that pregnenolone, a neurosteroid, can protect the brain from the intoxicating effects of cannabis (THC). Pregnenolone reduced the cognitive impairments caused by THC in animal models. This suggests that pregnenolone may have potential therapeutic applications in mitigating the adverse effects of cannabis use, particularly in cognitive function.
For further details visit https://www.science.org/doi/abs/10.1126/science.1243985
Blum K, Oscar-Berman M, Braverman ER, Febo M, Li M, Gold MS. Enhancing Brain Pregnenolone May Protect Cannabis Intoxication but Should Not Be Considered as an Anti-addiction Therapeutic: Hypothesizing Dopaminergic Blockade and Promoting Anti-Reward. Journal of reward deficiency syndrome. 2015;1(1):20-23. doi:10.17756/jrds.2015-005.
Enhancing Brain Pregnenolone May Protect Cannabis Intoxication but Should Not Be Considered as an Anti-addiction Therapeutic
The paper by Blum et al. suggests that enhancing brain pregnenolone levels may protect against the intoxicating effects of cannabis but should not be considered an anti-addiction therapy. The authors hypothesize that pregnenolone may work by blocking dopaminergic signaling and promoting anti-reward pathways. While it may reduce the acute effects of cannabis, it may not address the underlying addictive behaviors associated with cannabis use. The paper highlights the complex nature of addiction and suggests that a comprehensive approach is needed to address addiction effectively.
For further details visit https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545660/
Vallée M, Vitiello S, Bellocchio L, Hébert-Chatelain E, Monlezun S, et al. Pregnenolone can protect the brain from cannabis intoxication. Science. 2014;343(6166):94–98. doi: 10.1126/science.1243985.
Pregnenolone can protect the brain from cannabis intoxication
The study by Vallée et al. demonstrates that pregnenolone, a natural steroid, can protect the brain from the intoxicating effects of cannabis. Pregnenolone acts by inhibiting the activity of the endocannabinoid system, which is activated by cannabis. This protective effect suggests a potential therapeutic approach to mitigate the adverse cognitive and psychiatric effects of cannabis use.
For further details visit https://www.science.org/doi/abs/10.1126/science.1243985
Tuckey RC, Atkinson HC. Pregnenolone synthesis from cholesterol and hydroxycholesterols by mitochondria from ovaries following the stimulation of immature rats with pregnant mare’s serum gonadotropin and human choriogonadotropin. European journal of biochemistry. 1989; 186(1-2):255-9.
Pregnenolone synthesis from cholesterol and hydroxycholesterols by mitochondria from ovaries following the stimulation of immature rats with pregnant mare’s serum gonadotropin and human choriogonadotropin
The study by Tuckey and Atkinson investigated pregnenolone synthesis in rat ovaries following stimulation with a pregnant mare’s serum gonadotropin and human choriogonadotropin. They found that mitochondria in the ovaries were capable of converting cholesterol and hydroxycholesterols into pregnenolone, a crucial step in steroid hormone production. This research sheds light on the mechanisms involved in the synthesis of pregnenolone in the ovaries and its relevance to reproductive physiology.
For further details visit https://febs.onlinelibrary.wiley.com/doi/abs/10.1111/j.1432-1033.1989.tb15203.x
Burstein S, Gut M. Intermediates in the conversion of cholesterol to pregnenolone: kinetics and mechanism. Steroids. 1976; 28(1):115-31.
Intermediates in the conversion of cholesterol to pregnenolone
The study by Burstein and Gut explored the kinetics and mechanisms involved in the conversion of cholesterol to pregnenolone, a critical step in steroid hormone synthesis. They investigated various intermediates in this process, providing insights into the enzymatic reactions and reaction rates that facilitate the production of pregnenolone from cholesterol. This research contributes to our understanding of the biochemical pathways responsible for steroid hormone production in the body.
For further details visit https://www.sciencedirect.com/science/article/pii/0039128X76901318
Ohta Y, Mitani F, Ishimura Y, Yanagibashi K, Kawamura M, Kawato S. Conversion of cholesterol to pregnenolone mobilizes cytochrome P-450 in the inner membrane of adrenocortical mitochondria: protein rotation study. Journal of biochemistry. 1990; 107(1):97-104.
Conversion of cholesterol to pregnenolone mobilizes cytochrome P-450 in the inner membrane of adrenocortical mitochondria: protein rotation study
The study by Ohta et al. investigated the conversion of cholesterol to pregnenolone in adrenocortical mitochondria and its impact on cytochrome P-450. They conducted a protein rotation study to understand the dynamics of this process. The research revealed that the conversion of cholesterol to pregnenolone is associated with the mobilization of cytochrome P-450 within the inner membrane of adrenocortical mitochondria. This study provides valuable insights into the biochemical mechanisms underlying steroid hormone synthesis in the adrenal cortex.
For further details visit https://www.jstage.jst.go.jp/article/biochemistry1922/107/1/107_1_97/_article/-char/ja/
Shikita M, Hall PF. The Stoichiometry of the Conversion of Cholesterol and Hydroxycholesterols to Pregnenolone (3β-Hydroxypregn-5-en-20-one) Catalysed by Adrenal Cytochrome P-450. Proceedings of the National Academy of Sciences of the United States of America. 1974;71(4):1441-1445.
The Stoichiometry of the Conversion of Cholesterol and Hydroxycholesterols to Pregnenolone (3β-Hydroxypregn-5-en-20-one) Catalysed by Adrenal Cytochrome P-450
In the study by Shikita and Hall, the stoichiometry of the conversion of cholesterol and hydroxycholesterols to pregnenolone by adrenal cytochrome P-450 was investigated. The research aimed to determine the quantitative aspects of this conversion process. The study provided important insights into the enzymatic reactions involved in the synthesis of pregnenolone, a key precursor in steroid hormone biosynthesis. The findings contributed to our understanding of the regulation of steroid hormone production in the adrenal gland.
For further details visit https://www.pnas.org/doi/abs/10.1073/pnas.71.4.1441
Provencher PH, Roy R, Bélanger A. Pregnenolone fatty acid esters incorporated into lipoproteins: substrates in adrenal steroidogenesis. Endocrinology. 1992; 130(5):2717-24.
Pregnenolone fatty acid esters incorporated into lipoproteins
In the study by Provencher et al., the researchers investigated the incorporation of pregnenolone fatty acid esters into lipoproteins and their role as substrates in adrenal steroidogenesis. This research focused on understanding how pregnenolone, a precursor in steroid hormone synthesis, is transported within the bloodstream and utilized by the adrenal glands for steroid hormone production. The study provided insights into the mechanisms by which pregnenolone is transported and made available for steroidogenesis in the adrenal glands, contributing to our understanding of adrenal steroid hormone regulation.
For further details visit https://academic.oup.com/endo/article-abstract/130/5/2717/3034454
Leinonen P, Hammond GL, Vihko R. Testosterone and some of its precursors and metabolites in the human epididymis. The Journal of clinical endocrinology and metabolism. 1980; 51(3):423-8.
Testosterone and some of its precursors and metabolites in the human epididymis
In the study by Leinonen et al., the researchers investigated the presence of testosterone and its precursors and metabolites in the human epididymis. The epididymis is an important organ in the male reproductive system. This research aimed to understand the local production and regulation of testosterone within the epididymal tissue, shedding light on its potential role in sperm maturation and function. The study provided valuable insights into the hormonal environment of the epididymis, which is crucial for the development and maintenance of spermatozoa.
For further details visit https://academic.oup.com/jcem/article-abstract/51/3/423/2677972
Leinonen P, Hammond GL, Vihko R. Testosterone and some of its precursors and metabolites in the human epididymis. The Journal of clinical endocrinology and metabolism. 1980; 51(3):423-8.
Testosterone and some of its precursors and metabolites in the human epididymis
In the study by Leinonen et al. (1980), the researchers examined the presence of testosterone and its precursor and metabolites in the human epididymis. The epididymis is an essential component of the male reproductive system involved in sperm maturation. This research aimed to understand the local production and regulation of testosterone within the epididymal tissue, shedding light on its potential role in sperm development and function. The study provided valuable insights into the hormonal environment of the epididymis, which is crucial for the maturation and maintenance of spermatozoa.
For further details visit https://academic.oup.com/jcem/article-abstract/51/3/423/2677972
Holt JA, Wittmaack FM, Schreiber JR, Ghosh DK, Menon KM. Estrogen increases precursor for pregnenolone synthesis with temperature-sensitive occupancy of P-450scc in mitochondria of rabbit corpus luteum. Endocrinology. 1988; 122(5):1948-57.
Estrogen increases precursor for pregnenolone synthesis with temperature-sensitive occupancy of P-450scc in mitochondria of rabbit corpus luteum
In the study by Holt et al. (1988), the researchers investigated the effects of estrogen on the synthesis of pregnenolone, a precursor to steroid hormones, in the mitochondria of the rabbit corpus luteum. They found that estrogen increased the precursor for pregnenolone synthesis and influenced the occupancy of P-450scc, an enzyme involved in steroid synthesis, in a temperature-sensitive manner. This research provided insights into the regulation of steroid hormone production in the corpus luteum and the role of estrogen in modulating these processes.
For further details visit https://academic.oup.com/endo/article-abstract/122/5/1948/2531095
Craig ZR, Hannon PR, Flaws JA. Pregnenolone co-treatment partially restores steroidogenesis but, does not prevent growth inhibition and increased atresia in mouse ovarian antral follicles treated with mono-hydroxy methoxychlor. Toxicology and applied pharmacology. 2013;272(3):780-786. doi:10.1016/j.taap.2013.08.002.
Pregnenolone co-treatment partially restores steroidogenesis but, does not prevent growth inhibition and increased atresia in mouse ovarian antral follicles treated with mono-hydroxy methoxychlor
In the study by Craig et al. (2013), the researchers investigated the effects of pregnenolone co-treatment on mouse ovarian antral follicles treated with mono-hydroxy methoxychlor (mono-OH MXC), a potential environmental endocrine disruptor. They found that pregnenolone co-treatment partially restored steroidogenesis (the production of steroid hormones) but did not prevent the growth inhibition and increased atresia (follicle degeneration) induced by mono-OH MXC. This suggests that while pregnenolone had some protective effects on steroid hormone production, it was not able to fully counteract the adverse effects of mono-OH MXC on ovarian follicles.
For further details visit https://www.sciencedirect.com/science/article/pii/S0041008X13003402
Pregnenolone is a steroid hormone manufactured primarily in the adrenal glands, similar to testosterone, DHEA, and other sex hormones. Smaller amounts of pregnenolone are also produced in other organs such as the brain, skin, gonads, liver, and eyes. Among women, adequate pregnenolone is essential in treating overall hormone imbalance, symptoms related to menopause, and maintaining a positive mood.
In the body, all hormones work in harmony to create a healthy balance. If you picture steroid hormones as a cascade, where one hormone has an impact on one another, pregnenolone would be at the top of the cascade. Because of this, some researchers have nicknamed pregnenolone the “master hormone” or “mother hormone.”
Pregnenolone is manufactured directly from cholesterol. Some experts believe that low cholesterol can lead to hormone imbalance because your body doesn’t have sufficient raw material to produce enough pregnenolone. This in turn would affect levels of estrogen, DHEA, testosterone, and other hormones synthesized from pregnenolone.
Pregnenolone is also used to create neurohormones in the brain. These neurohormones are used to regulate mood, meaning it’s essential to maintain adequate pregnenolone to avoid mood-related disorders.
Unfortunately, there is still much we don’t know about pregnenolone, mostly because the research community has focused on steroid hormones like estrogen and progesterone. In the 1940s, when the focus of research is on how adrenal hormones worked, pregnenolone was extensively studied together with cortisol as an anti-inflammatory. In the 1950s, researchers discovered how to make synthetic cortisol, so the study of pregnenolone declined. Because pregnenolone, unlike cortisone, couldn’t be patented, there was no financial incentive to pursue the research.
Today, pregnenolone is used to improve energy, vision, memory, cognition, well-being, and sexual enjoyment or libido. It is considered a brain enhancer, and studies have shown that it is one of the most effective and powerful memory boosters. Women use pregnenolone for treatment of lumpy breasts (fibrocystic breast disease), endometriosis (disorder in the lining of the uterus), hot flashes, and other premenstrual symptoms.
As women age, levels of pregnenolone can fall as much as 60 percent. Researchers have linked this decline to depression, anxiety, cognitive impairment, and other mental illness. In women, low levels of pregnenolone are associated with low energy and mood and increased symptoms of menstruation. Other symptoms related to low pregnenolone include:
|
|
Women are at higher risk for hormone imbalance, thanks to their more complicated hormonal picture. Because of its role as the mother hormone, pregnenolone is frequently included in bioidentical hormone programs so there is plenty of material to make other sex hormones. Pregnenolone is also used to help relieve various symptoms of menopause. Other benefits of pregnenolone include:
|
|
With pregnenolone supplementation, the goal is to support overall healthy levels of pregnenolone in order to stimulate the body to produce internal pregnenolone in areas that need a boost of another steroid hormone. Pregnenolone is available in the form of injections, tablets, and topical creams.
Pregnenolone is a steroid hormone similar to testosterone, DHEA and other sex hormones. It is manufactured primarily in the adrenal glands, but smaller amounts are also produced in other organs including the skin, brain, gonads, liver and even the eyes.
In the body, all hormones work together to create a healthy balance. If you picture steroid hormones as a cascade, where one hormone affects another, and hormones can be synthesized from each other, pregnenolone would be at the top of the cascade. It’s manufactured directly from cholesterol (which is one reason that some experts believe excessively low cholesterol can actually contribute to a hormone imbalance). In turn, other hormones such as testosterone, DHEA, estrogen, and cortisol are synthesized from pregnenolone. Low pregnenolone levels are directly related to an overall deficiency in other, more biologically active hormones.
Pregnenolone is also highly concentrated in the brain, where it helps maintain cognitive health and healthy brain function. Just as it’s used to synthesize other steroid hormones, pregnenolone is used to create neurohormones in the brain, which act to support healthy nerve cell function and regulate mood. Because pregnenolone levels fall dramatically with age, as much as 60 percent, some researchers have linked pregnenolone deficiency in older adults to depression, anxiety, cognitive deficits and mental illness.
Besides acting as the main precursor for most steroid hormones, pregnenolone has a number of important functions in the body. Low levels of pregnenolone have been linked to memory problems and cognitive deficits, fatigue and low energy, low mood, and even increased symptoms of menstruation.
Unfortunately, researchers haven’t focused on the specific effects of pregnenolone in the body. This has more to do with how drugs are researched than it has to do with pregnenolone. In the 1940s, when researchers were just beginning to unravel how adrenal hormones worked, pregnenolone was extensively studied alongside cortisol for the relief of inflammatory conditions such as arthritis. In the 1950s, however, researchers figured out how to make synthetic cortisol, so the research focused on the more profitable hormone and the study of pregnenolone by itself declined.
Because of its role as the body’s main steroid hormone precursor, pregnenolone is typically included in a comprehensive hormone panel. Low levels are often indicative of an overall hormone imbalance and deficiency. However, it’s hard to isolate specific symptoms caused by low pregnenolone because these symptoms likely overlap with more powerful downstream hormones such as testosterone.
|
|
Bioidentical hormone replacement programs tend to use pregnenolone as a general balancing hormone. There is some evidence that healthy pregnenolone levels support overall healthy hormone levels, as well as boost the immune system, reduce stress and prolong life. Pregnenolone is effectively used alongside testosterone and estrogen to help relieve symptoms of estrogen imbalance, andropause and testosterone deficiency in men.
|
|
In the body, which hormone created from pregnenolone depends on where the pregnenolone is synthesized. For example, pregnenolone which is synthesized in the adrenal glands (the majority of it) is likely to be used to create cortisone or the body’s main stress hormone. Pregnenolone synthesized in the ovaries, by contrast, is likely to be used to synthesize estrogen. With pregnenolone supplementation, the goal is to support overall healthy levels of pregnenolone, which encourages the body to make internal pregnenolone in areas that need a boost of another steroid hormone. Pregnenolone can also be applied topically, and there is some evidence it can reduce wrinkles and improve skin elasticity.
At the age of 60, I look and feel better than I ever have in my entire life! Switching my health program and hormone replacement therapy regimen over to Genemedics was one of the best decisions I’ve ever made in my life! Genemedics and Dr George have significantly improved my quality of life and also dramatically improved my overall health. I hav...
Nick Cassavetes ,60 yrs old
Movie Director (“The Notebook”, “John Q”, “Alpha Dog”), Actor and Writer
I am now in my mid-sixties and feel better than I did in my 20’s. Many people have commented that I actually look 20 years younger since I started the program at Genemedics.
Calling Dr. George has proven to be one of the best decisions I have made in my life. Doctors and society convince us that developing various health issues and negative sy...
Pamela Hill ,66 yrs old
Call 800-277-4041 for a Free Consultation
Call 800-277-4041 for a Free Consultation
Call 800-277-4041 for a Free Consultation
Genemedics® Health Institute is a global premier institute dedicated to revolutionizing health and medicine through healthy lifestyle education, guidance and accountability in harmony with functional medicine. Our physician-supervised health programs are personally customized to help you reach your health and fitness goals while looking and feeling better than ever.
© Copyright Genemedics Health Institute. All Rights Reserved. Privacy Policy.
STEPS AWAY FROM A YOUNGER. HEALTHIER YOU!
Call 800-277-4041 for a Free Consultation
What to expect during your consultation: